These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
| Filed by the Registrant þ | |
| Filed by a Party other than the Registrant o | |
| Check the appropriate box: |
| o Preliminary Proxy Statement | |
| o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| þ Definitive Proxy Statement | |
| o Definitive Additional Materials | |
| o Soliciting Material Pursuant to §240.14a-12 |
ZIMMER HOLDINGS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| þ No fee required. | |
| o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| 1) Title of each class of securities to which transaction applies: |
| 2) Aggregate number of securities to which transaction applies: |
| 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
| 4) Proposed maximum aggregate value of transaction: |
| 5) Total fee paid: |
| o Fee paid previously with preliminary materials. |
| o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| 1) Amount Previously Paid: |
| 2) Form, Schedule or Registration Statement No.: |
| 3) Filing Party: |
| 4) Date Filed: |
| SEC 1913 (02-02) | Persons who potentially are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
|
TIME AND DATE
|
9:00 a.m. Eastern Time on Monday, May 2, 2011 | |
|
PLACE
|
Conrad Indianapolis 50 West Washington Street Indianapolis, Indiana |
|
ITEMS OF BUSINESS
|
| Elect eight directors to serve until the 2012 annual meeting of stockholders | ||
| | Cast a non-binding advisory vote on executive compensation (say-on-pay) | |||
| | Cast a non-binding advisory vote on the frequency of say-on-pay votes | |||
| | Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2011 | |||
| | Transact such other business as may properly come before the meeting and any postponement(s) or adjournment(s) thereof |
|
RECORD DATE
|
March 3, 2011 | |
|
ANNUAL REPORT
|
This booklet contains our Notice of Annual Meeting of Stockholders and Proxy Statement. Our 2010 Annual Report, which includes our Annual Report on Form 10-K for the year ended December 31, 2010, accompanies this booklet. Our 2010 Annual Report is not a part of our proxy solicitation materials. | |
|
VOTING
|
Your Vote Is Important. You are cordially invited to attend the annual meeting in person. To ensure your shares will be voted at the annual meeting, however, we strongly urge you to review the proxy statement and vote your shares as soon as possible. |
| TABLE OF CONTENTS | ||||
| PAGE | ||||
| 1 | ||||
| 1 | ||||
| 1 | ||||
| 1 | ||||
| 1 | ||||
| 1 | ||||
| 1 | ||||
| 2 | ||||
| 2 | ||||
| 2 | ||||
| 2 | ||||
| 2 | ||||
| 2 | ||||
| 3 | ||||
| 3 | ||||
| 3 | ||||
| 3 | ||||
| 3 | ||||
| 3 | ||||
| 3 | ||||
| 4 | ||||
| 4 | ||||
| 4 | ||||
| 4 | ||||
| 4 | ||||
| 5 | ||||
| 10 | ||||
| 11 | ||||
| 12 | ||||
| 13 | ||||
| 13 | ||||
| 14 | ||||
| 14 | ||||
| 14 | ||||
| 18 | ||||
| 19 | ||||
| 22 | ||||
| 24 | ||||
| 24 | ||||
| 39 | ||||
| 40 | ||||
| 41 | ||||
| 41 | ||||
| 44 | ||||
| 46 | ||||
| 47 | ||||
| 48 | ||||
| 50 | ||||
| 53 | ||||
| 58 | ||||
| 59 | ||||
| 60 | ||||
| | Election of directors (Proposal No. 1); | |
| | Advisory vote on executive compensation (say-on-pay) as disclosed in this proxy statement (Proposal No. 2); | |
| | Advisory vote on the frequency of say-on-pay votes (Proposal No. 3); and | |
| | Ratification of the appointment of PricewaterhouseCoopers LLP (PwC) as our independent registered public accounting firm for 2011 (Proposal No. 4). |
| | FOR the election of each of the eight nominees to the Board (Proposal No. 1); | |
| | FOR the say-on-pay proposal (Proposal No. 2); | |
| | 1 Year on the frequency of say-on-pay votes (Proposal No. 3); and | |
| | FOR ratification of the appointment of PwC as our independent registered public accounting firm for 2011 (Proposal No. 4). |
| | are present and vote in person at the annual meeting; or | |
| | have voted on the Internet, by telephone or by properly submitting a proxy card or vote instruction form by mail. |
| | Election of directors. For Proposal No. 1, nominees for director who receive the majority of votes cast will be elected as a director. The number of shares voted for a nominee must exceed the number of votes against that nominee. In the event the number of nominees exceeds the number of directors to be elected, the nominees who receive the most votes will be elected as directors. | |
| | Advisory say-on-pay vote. For Proposal No. 2, the affirmative vote of a majority of the shares present in person or by proxy is required to approve, by non-binding vote, executive compensation. | |
| | Advisory vote on the frequency of say-on-pay votes. For Proposal No. 3, the affirmative vote of a majority of the shares present in person or by proxy is required to approve, by non-binding vote, the frequency of future say-on-pay votes. | |
| | Ratification of the appointment of PwC. For Proposal No. 4, the affirmative vote of a majority of the shares present in person or by proxy is required to ratify the appointment of PwC as our independent registered public accounting firm. |
| | Stockholder of Record. If your shares are registered directly in your name with our transfer agent, BNY Mellon, you are considered the stockholder of record with respect to those shares, and the Notice was sent directly to you. If you request printed copies of the proxy materials by mail, you will receive a proxy card. | |
| | Beneficial Owner of Shares Held in Street Name. If your shares are held in an account at a brokerage firm, bank, broker dealer, or other similar organization, then you are the beneficial owner of shares held in street name, and the Notice was forwarded to you by that organization. The organization holding your account is considered the stockholder of record for purposes of voting at the annual meeting. As a beneficial owner, you have the right to instruct the record holder on how to vote the shares held in your account. Those instructions are contained in a vote instruction form. If you request printed copies of the proxy materials by mail, you will receive a vote instruction form. |
| | In person. If you are a stockholder of record, you may vote in person at the annual meeting. We will give you a ballot when you arrive. | |
| | Via the Internet. You may vote by proxy via the Internet by following the instructions provided in the Notice. | |
| | By Telephone. If you request printed copies of the proxy materials by mail, you may vote by proxy by calling the toll free number found on the proxy card. | |
| | By Mail. If you request printed copies of the proxy materials by mail, you may vote by proxy by filling out the proxy card and sending it back in the envelope provided. |
| | In person. If you are a beneficial owner of shares held in street name and you wish to vote in person at the annual meeting, you must obtain a legal proxy from the record holder of your shares. Please contact that organization for instructions regarding obtaining a legal proxy. |
| | Via the Internet. You may vote by proxy via the Internet by following the instructions provided in the Notice. | |
| | By Telephone. If you request printed copies of the proxy materials by mail, you may vote by proxy by calling the toll free number found on the vote instruction form. | |
| | By Mail. If you request printed copies of the proxy materials by mail, you may vote by proxy by filling out the vote instruction form and sending it back in the envelope provided. |
| | as necessary to meet applicable legal requirements; | |
| | to allow for the tabulation and certification of votes; and | |
| | to facilitate a successful proxy solicitation. |
| | revoking it by written notice to our Corporate Secretary at the address shown on the cover of this proxy statement; | |
| | delivering a later-dated proxy (including a telephone or Internet vote); or | |
| | voting in person at the meeting. |
| | Stockholders of Record. If you are a stockholder of record and you indicate when voting on the Internet or by telephone that you wish to vote as recommended by the Board, or sign and return a proxy card without giving specific voting instructions, then the proxy holders will vote your shares in the manner recommended by the Board on all matters presented in this proxy statement and as the proxy holders may determine in their discretion with respect to any other matters properly presented for a vote at the annual meeting. See the section entitled Other Matters below. | |
| | Beneficial Owners of Shares Held in Street Name. If you are a beneficial owner of shares held in street name and do not provide the record holder of your shares with specific voting instructions, your record holder may vote on the ratification of the appointment of PwC as our independent registered public accounting firm for 2011 (Proposal No. 4). However, your record holder cannot vote your shares without specific instructions on the election of directors (Proposal No. 1), the advisory say-on-pay vote (Proposal No. 2) or the advisory vote on the frequency of say-on-pay votes (Proposal No. 3). If your record holder does not receive instructions from you on how to vote your shares on Proposals 1, 2 or 3, your record holder will inform the inspector of election that it does not have the authority to vote on that proposal with respect to your shares. This is generally referred to as a broker non-vote. Broker non-votes will be counted as present for purposes of determining whether enough votes are present to hold the annual meeting, but they will not be counted in determining the outcome of the vote. |
| | forwarding the Notice to beneficial owners; | |
| | forwarding printed proxy materials by mail to beneficial owners who specifically request them; and | |
| | obtaining beneficial owners voting instructions. |
| | Requirements for Stockholder Proposals to Be Considered for Inclusion in our Proxy Materials. Stockholder proposals to be considered for inclusion in the proxy statement and form of proxy relating to the 2012 annual meeting of stockholders must be received no later than November 20, 2011. In addition, all proposals will need to comply with Rule 14a-8 of the Securities Exchange Act of 1934 (the Exchange Act), which lists the requirements for the inclusion of stockholder proposals in company-sponsored proxy materials. Stockholder proposals must be delivered to our Corporate Secretary by mail at the address shown on the cover page of this proxy statement. | |
| | Requirements for Stockholder Proposals to Be Brought Before the 2012 Annual Meeting of Stockholders. Notice of any director nomination or other proposal that you intend to present at the 2012 annual meeting of stockholders, but do not intend to have included in the proxy statement and form of proxy relating to the 2012 annual meeting of stockholders, must be delivered to our Corporate Secretary by mail at the address shown on the cover page of this proxy statement not earlier than the close of business on January 4, 2012 and not later than the close of business on February 3, 2012. In addition, your notice must set forth the information required by our Restated By-Laws with respect to each director nomination or other proposal that you intend to present at the 2012 annual meeting of stockholders. A copy of the by-law provisions may be obtained by contacting our Corporate Secretary. |
| Nominees for Director: 2011 2012 Term | ||
|
Betsy J. Bernard, Director Since 2009 President of AT&T Corp. from October 2002 until her retirement in December 2003. From April 2001 to October 2002, Ms. Bernard was Chief Executive Officer of AT&T Consumer. Prior to joining AT&T, Ms. Bernard held senior executive positions with Qwest Communications International Inc., US WEST, Inc., AVIRNEX Communications Group and Pacific Bell. Ms. Bernard currently serves on the board of directors of Principal Financial Group, Inc. and as chairman of the board of Telular Corporation and she previously served on the board of directors of BearingPoint, Inc., URS Corporation and United Technologies Corporation. Ms. Bernard received a B.A. degree from St. Lawrence University, an MBA from Fairleigh Dickenson University and an M.S. in management from Stanford Universitys Sloan Fellowship Program. Board Committees: Audit Committee, Compensation and Management Development Committee, Corporate Governance Committee and Science and Technology Committee. Age 55. |
|
| Key Qualifications, Experiences and Attributes: Betsy J. Bernards past experience as president and chief executive officer of leading global telecommunications companies has provided her with expertise in financial management, brand management, marketing, enterprise sales, customer care, operations, product management, electronic commerce and acquisitions. Ms. Bernards experience has led our Board of Directors to determine that she is an audit committee financial expert as that term is defined in SEC rules. She serves, and has served for more than 10 years, as a director of other public companies, including service as chairman of the board, and she has experience chairing the nominating and governance committees of other public companies. | ||
| Nominees for Director: 2011 2012 Term | ||
|
Marc N. Casper, Director Since 2009 President and Chief Executive Officer of Thermo Fisher Scientific Inc., or Thermo Fisher, since October 2009. Mr. Casper served as Executive Vice President and Chief Operating Officer of Thermo Fisher from May 2008 until he was named President and Chief Executive Officer. Following the merger of Thermo Electron Corporation and Fisher Scientific International Inc. in November 2006 until he was named Chief Operating Officer in May 2008, Mr. Casper served as Executive Vice President of Thermo Fisher and President of its Analytical Technologies businesses. From December 2003 to November 2006, Mr. Casper served as Senior Vice President of Thermo Electron Corporation. Mr. Casper joined Thermo Electron Corporation in December 2001 as President of its Life and Laboratory Sciences sector. He earned an MBA with high distinction from Harvard Business School and received a B.A. in economics from Wesleyan University. Mr. Casper is a director of Thermo Fisher and previously served as a director of The Advisory Board Company. Board Committees: Compensation and Management Development Committee and Corporate Governance Committee. Age 43. |
|
| Key Qualifications, Experiences and Attributes: Marc N. Casper has experience in executive roles, including his current role as chief executive officer of a leading provider of high-end analytical instruments, laboratory equipment and services to companies engaged in healthcare and scientific research. His executive experience has provided him with the ability to analyze and assess numerous aspects of a companys business. His background as an executive in the healthcare industry gives him significant knowledge and insight into our business and our industry. Mr. Casper serves, and has served for more than five years, as a director of other public companies. | ||
|
David C. Dvorak, Director Since 2007 President and Chief Executive Officer of the company since May 1, 2007. Prior to that, Mr. Dvorak served as Group President, Global Businesses and Chief Legal Officer from December 2005. From October 2003 to December 2005, Mr. Dvorak served as Executive Vice President, Corporate Services, Chief Counsel and Secretary, as well as Chief Compliance Officer. Mr. Dvorak was appointed Corporate Secretary in February 2003. He joined Zimmer in December 2001 as Senior Vice President, Corporate Affairs and General Counsel. Mr. Dvorak earned a B.S. in Business Administration (Finance) from Miami University (Ohio) and a J.D., magna cum laude, from Case Western Reserve University School of Law. He is a director of the Advanced Medical Technology Association, or AdvaMed, the medical device industrys trade association. Age 47. |
|
| Key Qualifications, Experiences and Attributes: David C. Dvorak, our President and Chief Executive Officer, is primarily responsible for carrying out the strategic plans and policies established by the Board and for giving direction and leadership toward the achievement of our goals and objectives. Mr. Dvorak served as our Group President, Global Businesses and Chief Legal Officer before being promoted to his current positions. In his prior roles, Mr. Dvorak had responsibility for our Dental, Spine, Trauma and Surgical divisions and for our global legal affairs. In addition, during his tenure with us, he also has had global responsibility for business development, human resources, quality assurance, regulatory affairs, clinical affairs, corporate compliance, government affairs and public relations. Mr. Dvoraks experience has given him in-depth knowledge of our global operations and significant experience in financial management, strategic planning, business integration and in dealing with the many regulatory aspects of our business. In addition, his position as a director of AdvaMed gives him a perspective broader than our own operations. | ||
| Nominees for Director: 2011 2012 Term | ||
|
Larry C. Glasscock, Director Since 2001 Chairman of WellPoint, Inc. from November 2005 until his retirement in March 2010. Mr. Glasscock also served as President and Chief Executive Officer of WellPoint, Inc. from November 2004 (following the merger between Anthem, Inc. and WellPoint Health Networks Inc.) until his retirement from day-to-day operations in June 2007. Prior to Anthems merger with WellPoint Health Networks in November 2004, Mr. Glasscock had served as Anthems President and Chief Executive Officer since 2001 and also as Anthems Chairman since 2003. Mr. Glasscock earned a B.B.A. from Cleveland State University. He also completed the Commercial Bank Management Program at Columbia University. Mr. Glasscock is a director of Sprint Nextel Corporation, Simon Property Group, Inc. and Sysco Corporation and previously served as a director of WellPoint, Inc. Board Committees: Audit Committee and Compensation and Management Development Committee. Age 62. |
|
| Key Qualifications, Experiences and Attributes: Larry C. Glasscocks past experience as chairman and chief executive officer of the nations leading health benefits company has provided him with in-depth knowledge of healthcare payment and reimbursement processes. His executive experience includes developing and implementing turnaround and growth strategies, designing enterprise risk management processes and developing talent and participating in successful leadership transitions. In addition, Mr. Glasscock also worked in financial services for over 20 years, where he developed financial and marketing skills, and in human resources for 4 years, where he gained a strong understanding of, and skills related to, compensation and benefits. Mr. Glasscocks experience has led our Board of Directors to determine that he is an audit committee financial expert as that term is defined in SEC rules. He serves, and has served for more than 10 years, as a director of other public companies. | ||
|
Robert A. Hagemann, Director Since 2008 Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated since August 1998. Mr. Hagemann joined Corning Life Sciences, Inc., a subsidiary of Quest Diagnostics former parent company, Corning Incorporated, in 1992, where he held a variety of senior financial positions before being named Vice President and Corporate Controller of Quest Diagnostics in 1996. Prior to joining Corning, Mr. Hagemann was employed by Prime Hospitality, Inc. and Crompton & Knowles, Inc. in senior financial positions. He was also previously employed by Arthur Young & Co., a predecessor company to Ernst & Young. Mr. Hagemann holds a B.S. in accounting from Rider University and an MBA from Seton Hall University. Board Committees: Audit Committee (Chair) and Corporate Governance Committee. Age 54. |
|
| Key Qualifications, Experiences and Attributes: Robert A. Hagemanns experience as the chief financial officer of the worlds leading provider of diagnostic testing, information and services that patients and doctors utilize to make better healthcare decisions has given him financial management expertise, as well as significant experience in strategic planning, business development, business integration, operations and information technology. Mr. Hagemanns experience has led our Board of Directors to determine that he is an audit committee financial expert as that term is defined in SEC rules. | ||
| Nominees for Director: 2011 2012 Term | ||
|
Arthur J. Higgins, Director Since 2007 Consultant, Blackstone Healthcare Partners of The Blackstone Group, since June 2010. Prior to that, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to joining Enzon Pharmaceuticals, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He is a past member of the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), a past member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and past President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Mr. Higgins is a director of Resverlogix Corp. and Ecolab Inc. Mr. Higgins graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry. Board Committees: Audit Committee and Compensation and Management Development Committee (Chair). Age 55. |
|
| Key Qualifications, Experiences and Attributes: Arthur J. Higgins has extensive senior leadership experience in the global healthcare market. Through leadership positions with large healthcare developers and manufacturers in both the United States and Europe, he has gained deep knowledge of the healthcare market and the strategies for developing and marketing products in this highly regulated area. This knowledge and industry background allow him to provide valuable insight to our growing healthcare business. In addition, his perspective gained from years of operating global businesses and his background in working with high growth companies fit well with our own plans for global growth and provide him experiences from which to draw to advise us on strategies for sustainable growth. Through his role as chief executive officer of the healthcare operations of a global enterprise with competencies in healthcare, nutrition and high-tech materials, he also gained significant exposure to enterprise risk management as well as quality and operating risk management necessary in a highly regulated industry such as healthcare. Mr. Higgins experience has led our Board of Directors to determine that he is an audit committee financial expert as that term is defined in SEC rules. | ||
|
John L. McGoldrick, Director Since 2001 and
Non-Executive Chairman since 2007 Special Advisor, International AIDS Vaccine Initiative, or IAVI, since September 2009. Senior Vice President, External Strategy Development, IAVI, from May 2006 until September 2009. Chairman, Association of State Colleges and Universities (NJ) since January 2009. Previously, Mr. McGoldrick served as Executive Vice President of Bristol-Myers Squibb Company from October 2005 until his retirement in April 2006. He held the position of Executive Vice President and General Counsel of Bristol-Myers Squibb from January 2000 to October 2005. Prior to that, he held the position of Senior Vice President, General Counsel and President, Medical Devices Group from December 1998 to January 2000. Mr. McGoldrick is a graduate of Harvard College and the Harvard Law School. Board Committees: Audit Committee, Compensation and Management Development Committee, Corporate Governance Committee (Chair) and Science and Technology Committee. Age 70. |
|
| Nominees for Director: 2011 2012 Term | ||
| Key Qualifications, Experiences and Attributes: John L. McGoldricks past legal and executive experience, including legal and executive positions with our former parent company, a major pharmaceutical company, has provided him with in-depth knowledge of the issues surrounding healthcare companies such as ours. In particular, he also oversaw the medical devices group of our former parent which provided him with extensive knowledge and understanding of our business and our industry. Mr. McGoldricks experience has led our Board of Directors to determine that he is an audit committee financial expert as that term is defined in SEC rules. | ||
|
Cecil B. Pickett, Ph.D., Director Since 2008 President, Research and Development of Biogen Idec Inc. from September 2006 until his retirement in October 2009. Prior to joining Biogen Idec, Dr. Pickett held several senior R&D positions, including Corporate Senior Vice President of Schering-Plough Corp. and President of Schering-Plough Research Institute. Prior to joining Schering-Plough, he held several senior R&D positions at Merck & Co. Dr. Pickett received his B.Sc. in biology from California State University at Hayward and his Ph.D. in cell biology from University of California at Los Angeles. He is also a member of the Institute of Medicine of The National Academy of Sciences. Dr. Pickett previously served as a director of Biogen Idec. Board Committees: Compensation and Management Development Committee, Corporate Governance Committee and Science and Technology Committee (Chair). Age 64. |
|
| Key Qualifications, Experiences and Attributes: Dr. Cecil B. Picketts past experience in research and development, including serving in senior R&D positions at a leading global biotechnology company and two leading global pharmaceutical companies, has provided him with knowledge of the innovation process and how to develop and market products in the highly regulated healthcare industry. Dr. Picketts scientific background allows him to give informed views on our own research and development efforts and processes. | ||
| | We emphasize long-term equity-based incentives and require a substantial ongoing equity ownership position for executives to align their interests with those of our stockholders. In 2010, 79% of our CEOs target total direct pay opportunity was attributable to long-term equity-based incentives, 11% was attributable to short-term cash incentives, and 10% was attributable to base salary. Our CEO must accumulate and hold shares with a value equal to at least five times his base salary. His current holdings exceed this guideline requirement. |
| | We emphasize at-risk performance-based compensation that is earned only if key business and financial metrics are achieved. In 2010, 52% of the CEOs pay was at-risk performance-based compensation in the form of performance-based restricted stock units (RSUs) and annual cash incentives. Another 38% of the CEOs 2010 pay was in the form of stock options that vest over a multi-year period and have value only to the extent our stock price increases. In aggregate, 90% of the CEOs pay was at-risk and/or contingent on stock price increases. |
| | We believe year-over-year increases in CEO pay should be primarily made in the form of at-risk performance-based compensation. Substantially all of the increase in our CEOs pay from 2009 to 2010 was attributable to at-risk performance-based compensation. Performance-based RSUs accounted for 94% of the increase in his pay. |
| | We apply clear performance measures that promote both long-term stockholder value creation and the consistent annual execution of our business plan. |
| | We have a policy of recoupment of performance-based compensation from any executive officer whose fraud or misconduct caused us to restate our financial statements or who violates a restrictive covenant contained in any agreement with us. |
| | We provide executive officers with a very limited range of perquisites or other benefits not generally available to all salaried employees. We do not provide executives with company cars or car allowances unless they are living overseas and such practices are consistent with local market practice. No executive officer used our aircraft for non-business purposes during 2010. |
| 2010 | 2009 | |||||||
|
Audit Fees
(1)
|
$4,329,000 | $4,233,000 | ||||||
|
Audit-Related Fees
(2)
|
99,000 | 63,000 | ||||||
|
Tax Fees
(3)
|
281,000 | 387,000 | ||||||
|
All Other Fees
(4)
|
7,000 | 6,000 | ||||||
|
Total Fees
|
$ | 4,716,000 | $ | 4,689,000 | ||||
| (1) | This category includes the audit of our annual financial statements, the audit of our internal control over financial reporting, the review of interim financial statements included in our quarterly reports on Form 10-Q and services that are normally provided by the independent registered public accounting firm in connection with statutory and regulatory filings or engagements for those years. This category also includes advice on accounting matters that arose during, or as a result of, the audit or the review of interim financial statements and statutory audits required by non-U.S. jurisdictions. | |
| (2) | This category consists of assurance and related services provided by PwC that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under Audit Fees. The services for the fees disclosed under this category include attest services related to non-statutory financial reporting outside the U.S., employee benefit plan audits, accounting research and consultation and restructuring-related statutory reports for various countries. | |
| (3) | This category consists of tax services provided by PwC for tax compliance, tax advice and tax planning. | |
| (4) | This category consists primarily of software purchases in connection with statutory audits in non-U.S. jurisdictions. |
| Common Stock Beneficially Owned (1) | ||||||||||||||||
|
Total |
Shares |
Deferred |
Percent |
|||||||||||||
|
Shares |
Acquirable in |
Share |
of |
|||||||||||||
|
Beneficial Owner
|
Owned(2) | 60 Days(3) | Units(3) |
Class
|
||||||||||||
| (a) | (b) | (c) | (d) | (e) | ||||||||||||
|
Non-Employee Directors
|
||||||||||||||||
|
Betsy J. Bernard
|
1,993 | 0 | 1,993 | * | ||||||||||||
|
Marc N. Casper
|
1,993 | 0 | 1,993 | * | ||||||||||||
|
Larry C. Glasscock
|
67,891 | (4) | 61,608 | 6,243 | * | |||||||||||
|
Robert A. Hagemann
|
2,920 | 0 | 2,920 | * | ||||||||||||
|
Arthur J. Higgins
|
3,355 | 441 | 2,914 | * | ||||||||||||
|
John L. McGoldrick
|
27,773 | 9,401 | 7,040 | * | ||||||||||||
|
Cecil B. Pickett, Ph.D.
|
2,920 | 0 | 2,920 | * | ||||||||||||
|
Named Executive Officers
|
||||||||||||||||
|
David C. Dvorak
|
810,743 | 740,028 | 0 | * | ||||||||||||
|
James T. Crines
|
359,253 | 326,057 | 0 | * | ||||||||||||
|
Bruno A. Melzi
|
355,053 | 279,727 | 0 | * | ||||||||||||
|
Jeffery A. McCaulley
|
77,589 | 60,319 | 0 | * | ||||||||||||
|
Jeffrey B. Paulsen
|
6,375 | 6,375 | 0 | * | ||||||||||||
|
All current directors and executive officers as a group
(16 persons)
|
2,349,835 | 2,066,438 | 26,023 | 1.2 | % | |||||||||||
| * | Less than 1.0% | |
| (1) | Unless otherwise noted, shares are owned directly or indirectly with sole voting and dispositive power. None of the shares owned by our directors and executive officers have been pledged as security. | |
| (2) | Includes shares owned directly and indirectly, shares acquirable in 60 days (column (c)), deferred share units (column (d)) and the following restricted shares, which are subject to vesting requirements: Mr. Dvorak 15,022; Mr. Crines 7,510; Mr. McCaulley 17,270; and all directors and executive officers as a group 39,802. | |
| (3) | A beneficial owner of stock is a person who has sole or shared voting power, meaning the power to control voting decisions, or sole or shared investment power, meaning the power to cause the sale of the stock. A person is also considered the beneficial owner of shares as to which the person has the right to acquire beneficial ownership (within the meaning of the preceding sentence) within 60 days. For this reason, the table includes exercisable stock options, stock options that will become exercisable within 60 days of January 3, 2011, shares underlying RSUs that are scheduled to settle within 60 days of January 3, 2011 and vested RSUs and deferred share units held by directors that would be settled in shares of our common stock within 60 days at the discretion of the director (e.g., upon retirement). The table does not include stock options or RSUs held by executive officers that vest more than 60 days after January 3, 2011. It also does not include vested RSUs held by directors that are subject to mandatory deferral of settlement until May 2011 or later. | |
| (4) | Includes 40 shares held in a trust with respect to which Mr. Glasscock shares voting authority with the trustee. |
| | presiding at meetings of the Board and stockholders; | |
| | approving the agendas for meetings of the full Board, as prepared by the CEO; | |
| | presiding at meetings of the non-management directors; | |
| | coordinating the activities of the non-management directors; and | |
| | serving as the liaison between the CEO and the rest of the Board. |
|
Compensation |
||||||||
|
and |
Science |
|||||||
|
Management |
Corporate |
and |
||||||
|
Director
|
Audit | Development | Governance | Technology | ||||
|
Betsy J. Bernard
|
X | X | X | X | ||||
|
Marc N. Casper
|
X | X | ||||||
|
David C. Dvorak
|
||||||||
|
Larry C. Glasscock
|
X | X | ||||||
|
Robert A. Hagemann
|
Chair | X | ||||||
|
Arthur J. Higgins
|
X | Chair | ||||||
|
John L. McGoldrick
|
X | X | Chair | X | ||||
|
Cecil B. Pickett, Ph.D.
|
X | X | Chair | |||||
|
2010 Meetings
|
12 | 7 | 5 | 1 |
| | appointing, evaluating and, where appropriate, replacing our independent registered public accounting firm; | |
| | pre-approving all auditing services and permissible non-audit services provided to us by our independent registered public accounting firm; | |
| | reviewing with our independent registered public accounting firm and with management the proposed scope of the annual audit, past audit experience, our program for the internal examination and verification of our accounting records and the results of recently completed internal examinations; | |
| | resolving disagreements between management and our independent registered public accounting firm regarding financial reporting; | |
| | reviewing major issues as to the adequacy of our internal controls; and | |
| | overseeing our compliance with legal and regulatory matters and aspects of our risk management processes. |
| | administering our annual incentive, stock option and long-term incentive plans; | |
| | reviewing and making recommendations to the Board with respect to incentive compensation and equity-based plans; | |
| | approving compensation of executive officers; and | |
| | discussing with management the Compensation Discussion and Analysis required by SEC regulations and, if appropriate, recommending its inclusion in our Annual Report on Form 10-K and proxy statement. |
| | developing and recommending to the Board criteria for selection of non-management directors; | |
| | recommending director candidates to the Board; | |
| | periodically reviewing director performance; | |
| | periodically reassessing the Boards Corporate Governance Guidelines and recommending any proposed changes to the Board for approval; and | |
| | periodically reviewing, in cooperation with the Compensation and Management Development Committee, the form and amount of non-employee director compensation and recommending any proposed changes to the Board for approval. |
| | advising the Board on matters involving our new science and advanced technology programs, including major internal projects, interactions with academic and independent research organizations and the acquisition of technologies; and | |
| | reviewing and recommending to the Board major technology positions and strategies relative to emerging concepts of therapy, new trends in healthcare and changing market requirements. |
|
Fees Earned or Paid |
||||||||||||||||
|
in
Cash(1) |
Stock
Awards(2) |
Option
Awards(3) |
Total |
|||||||||||||
|
Name
|
($) | ($) | ($) | ($) | ||||||||||||
| (a) | (b) | (c) | (d) | (h) | ||||||||||||
|
Betsy J. Bernard
|
62,500 | 155,520 | | 218,020 | ||||||||||||
|
Marc N. Casper
|
49,000 | 155,520 | | 204,520 | ||||||||||||
|
Larry C. Glasscock
|
51,500 | 130,520 | 37,500 | 219,520 | ||||||||||||
|
Robert A. Hagemann
|
68,500 | 155,520 | | 224,020 | ||||||||||||
|
Arthur J. Higgins
|
92,000 | 130,520 | | 222,520 | ||||||||||||
|
John L. McGoldrick
|
135,500 | 130,520 | | 266,020 | ||||||||||||
|
Cecil B. Pickett, Ph.D.
|
60,625 | 155,520 | | 216,145 | ||||||||||||
|
Augustus A.
White, III, M.D., Ph.D.(4)
|
39,250 | 30,520 | | 69,770 | ||||||||||||
| (1) | Amounts include fees that were paid in cash plus fees that were voluntarily deferred at each directors election under our Restated Deferred Compensation Plan for Non-Employee Directors, or the Deferred Compensation Plan. As explained more fully below, compensation that a director elects to defer is credited to the directors deferred compensation account as either treasury units, dollar units or deferred share units, or DSUs, and will be paid in cash following the directors retirement or other termination of service from the Board. | |
| (2) | Represents the grant date fair value of the stock awards determined in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (ASC 718). For a discussion of the assumptions made in the valuation, see Note 3 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2010. |
| Ms. Bernard | Mr. Casper | Mr. Glasscock | Mr. Hagemann | Mr. Higgins | Mr. McGoldrick | Dr. Pickett | Dr. White | |||||||||||||||||||||||||
|
RSUs (granted 05-03-10) |
$ | 100,000 | $ | 100,000 | $ | 100,000 | $ | 100,000 | $ | 100,000 | $ | 100,000 | $ | 100,000 | $ | | ||||||||||||||||
|
DSUs (granted 05-03-10) |
30,520 | 30,520 | 30,520 | 30,520 | 30,520 | 30,520 | 30,520 | 30,520 | ||||||||||||||||||||||||
|
DSUs (mandatory deferral) |
25,000 | 25,000 | | 25,000 | | | 25,000 | | ||||||||||||||||||||||||
|
Total
|
$ | 155,520 | $ | 155,520 | $ | 130,520 | $ | 155,520 | $ | 130,520 | $ | 130,520 | $ | 155,520 | $ | 30,520 | ||||||||||||||||
| Ms. Bernard | Mr. Casper | Mr. Glasscock | Mr. Hagemann | Mr. Higgins | Mr. McGoldrick | Dr. Pickett | Dr. White | |||||||||||||||||||||||||
|
Number of RSUs
|
3,925 | 3,925 | 6,371 | 5,303 | 5,743 | 6,371 | 5,303 | 3,664 | ||||||||||||||||||||||||
|
Number of DSUs
|
1,993 | 1,993 | 6,243 | 2,920 | 2,914 | 7,040 | 2,920 | | ||||||||||||||||||||||||
|
Total
|
5,918 | 5,918 | 12,614 | 8,223 | 8,657 | 13,411 | 8,223 | 3,664 | ||||||||||||||||||||||||
| (3) | Represents the grant date fair value determined in accordance with ASC 718 with respect to stock options that were awarded to Mr. Glasscock in May 2010 pursuant to his election under the Deferred Compensation Plan to convert the portion of his annual retainer for Board service not subject to mandatory deferral into stock options. Under the terms of our Stock Plan for Non-Employee Directors, these stock options vested on December 31, 2010. |
|
Ms. |
Mr. |
Mr. |
Mr. |
Mr. |
Mr. |
|||||||||||||||||||||||||||
| Bernard | Casper | Glasscock | Hagemann | Higgins | McGoldrick | Dr. Pickett | Dr. White | |||||||||||||||||||||||||
|
Number of Shares Underlying Stock Options
|
| | 60,540 | | | 8,333 | | | ||||||||||||||||||||||||
| (4) | Dr. Whites term as a member of the Board of Directors ended May 3, 2010. |
| | We generated increased revenues, adjusted diluted earnings per share and operating cash flow as compared to 2009, despite a challenging global economic environment. We reported net sales of $4.22 billion for 2010, an increase of 3.0% over 2009. Adjusted diluted earnings per share were $4.33, an increase of 9.9% over 2009, and operating cash flow was $1.19 billion, an increase of 6.8% over 2009. Our solid earnings and strong bottom-line and cash flow performance resulted in slightly above-target payouts under our annual cash incentive program and our 2010 performance-based RSU award, which is subject to time-based vesting requirements through 2014. |
| | We made investments in innovation to drive sustained growth in earnings and cash flow and we returned value to stockholders. Due to the strong cash flow generated from our operations in 2010, we were able to invest $220.0 million in research and development while returning value to stockholders with the repurchase of approximately $505.5 million of common stock. |
| | We successfully executed several important product launches, which we believe will position us for accelerated growth as the economy strengthens. These include the Zimmer NexGen® LPS-Flex Mobile Bearing Knee with Prolong® Highly Crosslinked Polyethylene, our new patient specific and posterior referencing instrumentation systems, the Continuum® Acetabular System, the Zimmer NCB® (Non-Contact Bridging) Periprosthetic Plating System and the Zimmer Natural Nail® System. |
| | We demonstrated our commitment to invest globally in high-growth emerging markets and businesses. We completed the acquisitions of Beijing Montagne Medical Device Co., Ltd., further enhancing our presence in the rapidly growing Chinese market, and Geneva, Switzerland-based Sodem Diffusion S.A., strengthening our position in the over $1 billion surgical power tools market. |
| | We emphasize long-term equity-based incentives and require a substantial ongoing equity ownership position for executives to align their interests with those of our stockholders. In 2010, 79% of our CEOs target total direct pay opportunity was attributable to long-term equity-based incentives, 11% was attributable to short-term cash incentives, and 10% was attributable to base salary. Our CEO must accumulate and hold shares with a value equal to at least five times his base salary. His current holdings exceed this guideline requirement. |
| | We emphasize at-risk performance-based compensation that is earned only if key business and financial metrics are achieved. In 2010, 52% of the CEOs pay was at-risk performance-based compensation in the form of performance-based RSUs and annual cash incentives. Another 38% of the CEOs 2010 pay was in the form of stock options that vest over a multi-year period and have value only to the extent our stock price increases. In aggregate, 90% of the CEOs pay was at-risk and/or contingent on stock price increases. |
| | We believe year-over-year increases in CEO pay should be primarily made in the form of at-risk performance-based compensation. Substantially all of the increase in our CEOs pay from 2009 to 2010 |
| was attributable to at-risk performance-based compensation. Performance-based RSUs accounted for 94% of the increase in his pay. |
| | Attract and Retain a Highly Qualified and Effective Leadership Team. We design our program to be competitive with the organizations with which we compete for talent in order to attract, retain and motivate high-performing executives. |
| | Pay for Performance. We design our program to reward performance and the achievement of short- and long-term goals to achieve our strategic business plan. As executives assume positions of greater responsibility, a larger portion of their total compensation is at-risk incentive compensation tied to measures of our performance. In 2010, approximately 50% of named executives target total direct pay opportunity (base salary + target annual cash incentive opportunity + target long-term equity-based incentive value) was at-risk and contingent on the achievement of financial and individual performance measures. Approximately another 36% was in the form of stock options that vest over a multi-year period and have value only to the extent our stock price increases. |
| | Create Stockholder Alignment. We align the interests of our executives with stockholder interests through the use of equity-based incentives and stock ownership guidelines that facilitate a culture of ownership and reward executives for sustained and superior performance as measured by operating results and stockholder return. |
|
|
|
|
|
Compensation |
||||||
| Element | Objective | Key Features Specific to Executives | ||||
|
Base salary
|
To provide a fixed component of compensation, as a recruiting and retention tool and to recognize increased responsibilities through promotional increases. | Targeted at approximately the 50th percentile of market based on data derived from peer group and published compensation survey benchmarking data. The committee selected the 50th percentile as the positioning for base salary because it believes this is a reasonably competitive mid-point, appropriate for the only fixed component of compensation. | ||||
|
Annual cash
incentive (bonus) opportunities |
To focus our executives on pre-set financial objectives and drive specific behaviors that foster short-term and long-term growth and profitability. |
Targeted at approximately the 65th percentile of market. The committee believes targeting annual cash incentive opportunities at the 65th percentile of market is appropriate because of the high proportion of compensation that is variable, at risk and tied to our financial and operational performance.
Each executive is eligible for an annual award opportunity in an amount based upon a percentage of base salary. Consistent with our compensation objectives, as executives assume greater responsibilities, more of their pay is contingent on company performance. Payouts can range between 0% and 200% of the specified percentage of the executives base salary depending on our financial results relative to predetermined performance measures. The committee has the discretion to adjust a bonus payment downward (but not upward) from the amount yielded by the formula for executives based on individual performance and any other factors the committee deems relevant. |
||||
|
Long-term
equity-based incentives |
To motivate executives to drive the long-term performance of the company and to align their interests with those of stockholders. |
Targeted at approximately the 75th percentile of market on average. From 2008 through 2010, target grants to our named executives ranged between the 49th and 82nd percentiles of the peer group on average. The committee believes the emphasis on equity awards in our executive compensation program is appropriate as these officers have the greatest role in establishing the companys direction and should have the greatest proportion of their compensation aligned with the long-term interests of stockholders. Approximately 50% of the grant value of the 2010 target award was in the form of performance-based RSUs and the other 50% was in the form of stock options. Equity incentives are the most significant component of each named executives compensation package.
Performance-based RSUs are earned based on actual results relative to a predetermined performance measure and payouts can range from 0% to 150% of the target number of RSUs awarded. Earned RSUs that vest are settled in shares of common stock, on a one-for-one basis. Shares earned at the end of the one-year performance period will vest over the next three years, so that the earned shares are not fully vested until the fourth anniversary of the grant date. Stock options vest over four years and have value only to the extent our stock price rises after the grant date. |
||||
| Base salary | |||||||||
|
Percentage |
|||||||||
| Name | 2009 | 2010 | Increase | ||||||
|
Mr. Dvorak
|
$787,500 | $850,000 | 7.94% | ||||||
|
Mr. Crines
|
$475,300 | $494,300 | 4.00% | ||||||
|
Mr.
Melzi(1)
|
$577,538 | $566,273 | 2.75% | ||||||
|
Mr. McCaulley
|
$500,000 | $513,800 | 2.75% | ||||||
|
Mr. Paulsen
|
$465,000 | $465,000 | 0.00% | ||||||
| (1) | Mr. Melzis compensation is paid in Euros and has been converted to U.S. dollars for purposes of this table using the average exchange rate for 2009 and 2010 of 1 EUR = 1.3930 USD and 1 EUR = 1.32928 USD, respectively. The percentage increase is computed based on his salary in Euros before conversion to U.S. dollars (414,600 for 2009 and 426,000 for 2010). |
| EPIP award targets (as a percentage of base salary) | |||||||||
| Name | 2009 | 2010 | Change | ||||||
|
Mr. Dvorak
|
115% | 120% | 5% | ||||||
|
Mr. Crines
|
75% | 80% | 5% | ||||||
|
Mr. Melzi
|
65% | 75% | 10% | ||||||
|
Mr. McCaulley
|
70% | 80% | 10% | ||||||
|
Mr. Paulsen
|
N/A | 70% | N/A | ||||||
| EPIP performance measures target and actual performance | ||||||||||||||||||||||||||||||
|
Actual |
Actual |
|||||||||||||||||||||||||||||
|
(as Publicly |
(as |
|||||||||||||||||||||||||||||
|
Announced |
Reduced for |
Weighted |
||||||||||||||||||||||||||||
|
in Earnings |
Purposes of |
Achievement |
payout |
|||||||||||||||||||||||||||
| Financial performance measures | Target | Release) | EPIP) | Percentage (4) | Weight | percentage | ||||||||||||||||||||||||
|
Adjusted
EPS(1)
|
$ | 4.28/share | $ | 4.33/share | $ | 4.30/share | 100.5 | % | 50 | % | 51.2 | % | ||||||||||||||||||
| (In millions) | ||||||||||||||||||||||||||||||
|
Consolidated
revenue(2)
|
$ | 4,334 | $ | 4,220 | $ | 4,219 | 97.3 | % | 25 | % | 22.8 | % | ||||||||||||||||||
|
Consolidated free cash
flow(3)
|
$ | 808 | $ | 922 | $ | 860 | 106.4 | % | 25 | % | 33.0 | % | ||||||||||||||||||
| Total | 107.0 | % | ||||||||||||||||||||||||||||
| (1) | Adjusted EPS had to equal or exceed the target level ($4.28) in order for payments to exceed 100% of target. Consistent with past practice, the committee adjusted the results on which 2010 EPIP awards were determined to eliminate the effects of certain items. Adjusted EPS for purposes of the EPIP is calculated the same way it is calculated in our earnings announcements. The committee reviews all adjustments and retains discretion to reduce compensation below the amounts that are yielded by use of the adjusted EPS measure reported to the investment community. For 2010, the committee reduced adjusted EPS for purposes of the EPIP to eliminate three cents of EPS improvement attributable to share repurchases in excess of plan. As a result, 2010 adjusted EPS for purposes of the EPIP is calculated as follows: |
| Reconciliation of Adjusted EPS performance measure | 2010 | ||
|
EPS (as computed under Generally Accepted Accounting
Principles)
|
$2.97 | ||
|
Eliminate:
|
|||
|
amortization of acquisition-related inventory
step-up
|
0.01 | ||
|
acquisition and integration costs and employee
termination benefits and asset impairment charges connected with
global restructuring and transformation initiatives
|
0.17 | ||
|
provision for certain
Durom®
Acetabular Component product claims
|
0.37 | ||
|
goodwill impairment charge related to U.S. Spine
reporting unit
|
1.01 | ||
|
tax benefit of eliminated items
|
-0.20 | ||
|
Adjusted EPS (As Publicly Announced in Earnings Release)
|
$4.33 | ||
|
Eliminate favorable effect of share repurchases in excess of plan
|
-0.03 | ||
|
Adjusted EPS (As Reduced for Purposes of EPIP)
|
$4.30 | ||
| (2) | For 2010, the committee reduced actual consolidated revenue of $4.220 billion by $1 million for purposes of the EPIP to exclude the favorable effect of foreign currency translation in excess of budget. | |
| (3) | Consolidated free cash flow is net cash provided by operating activities ($1,194 million) less additions to instruments ($193 million) and other property, plant and equipment (PPE) ($79 million). For 2010, the committee reduced actual consolidated free cash flow of $922 million by $62 million for purposes of the EPIP to exclude the favorable effect of an under-spend in PPE relative to budget. | |
| (4) | The achievement percentage for each performance measure was applied to the following payout curve to determine the payout percentage for that measure. Achievement for each measure was capped at 120% of target and had a threshold of 85% of target with linear interpolation between the specified percentages. The resulting payout percentages were then weighted and summed to determine the total overall payout percentage of 107.0%. |
| EPIP payout curve applied to each performance measure | |||||
|
Payout |
|||||
| Achievement Percentage | Percentage | ||||
|
120%+
|
200% | ||||
|
100%
|
100% | ||||
|
85%
|
50% | ||||
|
Less than 85%
|
0% | ||||
| 2010 EPIP opportunities and actual payouts | |||||||||||
|
Opportunity |
Actual payment as a |
||||||||||
|
(at target |
Actual |
percentage of target |
|||||||||
| Name | performance) | Payment | opportunity | ||||||||
|
Mr. Dvorak
|
$991,298 | $ | 1,039,475 | 104.9% | |||||||
|
Mr. Crines
|
$385,980 | $ | 404,739 | 104.9% | |||||||
|
Mr. Melzi
(1)
|
$410,460 | $ | 426,016 | 103.8% | |||||||
|
Mr. McCaulley
|
$396,614 | $ | 415,890 | 104.9% | |||||||
|
Mr. Paulsen
|
$325,500 | $ | 341,319 | 104.9% | |||||||
| (1) | Mr. Melzis compensation is paid in Euros and has been converted to U.S. dollars for purposes of this table using the average exchange rate for 2010 of 1 EUR = 1.32928 USD. |
| 2010 performance-based RSUs target and actual performance | |||||||||||
|
Actual (as Publicly Announced |
Actual (as Reduced for Purposes of |
||||||||||
| Financial performance measures | Target | in Earnings Release) | EPIP and Performance-Based RSUs) | ||||||||
|
Adjusted EPS
(1)
|
$4.28/share | $ | 4.33/share | $4.30/share | |||||||
| (1) | See Annual Cash Incentives above for a calculation of adjusted EPS. As described above, actual 2010 adjusted EPS as publicly announced in our earnings release was $4.33. As with the EPIP, for purposes of the performance-based RSU award, the committee reduced adjusted EPS by three cents to eliminate the favorable effect of share repurchases in excess of plan. |
| 2010 performance-based RSUs opportunity and payout | |||||||||||
|
Opportunity (at target |
Actual number of |
Earned RSUs as a percentage |
|||||||||
| Name | company performance) | RSUs earned (1) | of target opportunity | ||||||||
|
Mr. Dvorak
|
62,700 | 63,691 | 101.6% | ||||||||
|
Mr. Crines
|
22,600 | 22,957 | 101.6% | ||||||||
|
Mr. Melzi
|
19,400 | 19,707 | 101.6% | ||||||||
|
Mr. McCaulley
|
19,400 | 19,707 | 101.6% | ||||||||
|
Mr. Paulsen
|
15,400 | 15,643 | 101.6% | ||||||||
| (1) | One-third of the earned RSUs will vest in each of 2012, 2013 and 2014. |
| | It coincides with our calendar-year-based performance management cycle, allowing supervisors to communicate the equity award decisions close in time to performance appraisals, which increases the impact of the awards by strengthening the link between pay and performance. |
| | It follows the annual earnings release and the filing of our Annual Report on Form 10-K. |
| | the average of the high and the low closing prices of our common stock on the grant date, and |
| | the same valuation methodology we use to determine the accounting expense of the grants under ASC 718. |
| Executive stock ownership guidelines | ||||||
| Name | Value of Zimmer stock required to be held | Meets guideline | ||||
|
Mr. Dvorak
|
$4,250,000 | Yes | ||||
|
Mr. Crines
|
$1,482,900 | Yes | ||||
|
Mr. Melzi
(1)
|
$1,698,820 | Yes | ||||
|
Mr. McCaulley
|
$1,541,400 | Yes | ||||
|
Mr. Paulsen
|
$1,395,000 | Yes | ||||
| (1) | Mr. Melzis compensation is paid in Euros. The stock ownership requirement applicable to Mr. Melzi has been converted to U.S. dollars for purposes of this table using the average exchange rate for 2010 of 1 EUR = 1.32928 USD. |
|
C.R. Bard, Inc.
|
Medtronic, Inc. | |
|
Beckman Coulter, Inc.
|
Quest Diagnostics Incorporated | |
|
Becton, Dickinson and Company
|
St. Jude Medical, Inc. | |
|
Boston Scientific Corporation
|
Stryker Corporation | |
|
Covidien Ltd.
|
Thermo Fisher Scientific Inc. | |
|
Hospira, Inc.
|
| | reviewing our long-term incentive plan design structure; |
| | reviewing financial goals for the annual and long-term incentive programs; |
| | performing a market review of executive officer compensation and preparing tally sheets that the committee considered when making compensation decisions; |
| | reviewing the composition of the peer group we use for executive compensation benchmarking purposes; |
| | reviewing current issues and trends in executive compensation; |
| | assisting with executive compensation disclosures for the annual proxy filing; |
| | reviewing the pay-for-performance alignment of our executive compensation programs; and |
| | assessing our executive compensation program and its relationship to organizational risk. The results of this assessment are discussed on page 40. |
| 2010 | ||||
|
Consulting Fees Related to Executive or Director Compensation
|
$ | 285,026 | ||
|
Consulting Fees Related to Health and Welfare Benefit Plans
|
817,085 | |||
|
Total
|
$ | 1,102,111 | ||
| | Neither the lead compensation consultant nor any member of his team participates in any of the other consulting services provided to us by Towers Watson; |
| | Neither the lead compensation consultant nor any member of his team is compensated or rewarded in any way for the other consulting services provided to us; and |
| | The committee has adopted a policy, described in more detail below, under which the committee must approve in advance all consulting services provided to us by Towers Watson and its affiliates. |
| | To the extent that a service can be forecasted in advance, approval may be given by the committee as part of the fee budget presented to the committee. |
| | With respect to a service that is identified after the budget is approved, the scope and cost of the service are to be provided to the Vice President, Global Compensation, Benefits and HRIS, who will arrange to obtain approval. |
| | The committee has delegated to its Chairman the authority to preapprove services to be provided by Towers Watson, provided that such services do not exceed an aggregate of $100,000 annually. |
| | Any approvals given by the Chairman using this delegation of authority are to be reported to the full committee at its next meeting. |
| | Annually, the committee is to receive a report of the total fees we paid to Towers Watson and its affiliates for executive or director compensation services and all other services. |
| | cash incentive compensation paid under the EPIP; and |
| | equity incentive awards granted to executive officers. |
| | The multiple elements of our compensation packages, including base salary, annual cash incentives and different forms of equity awards that vest over a number of years and are intended to motivate employees to take a long-term view of our business; |
| | Effective management processes for developing strategic and annual operating plans on which performance targets are based, and strong internal financial controls; |
| | Oversight of our programs by the Compensation and Management Development Committee, including approving target opportunities, financial and operating goals, and payouts; |
| | The use of financial performance measures in our incentive compensation plans that are derived from information we publicly announce in our earnings releases, and oversight of this information by the Audit Committee; |
| | Administration and oversight of plans and programs by multiple functions within the company (e.g., finance, legal and human resources); |
| | The annual review of executive compensation to assess the market competitiveness of pay, with further review of the historical relationship between pay and performance against peer companies; |
| | Stock ownership requirements that encourage long-term perspectives among participants; and |
| | A preference for performance measures that result in payments only upon achievement of ultimate financial results. |
|
Change in |
||||||||||||||||||||||||||||||||
|
Pension |
||||||||||||||||||||||||||||||||
|
Value and |
||||||||||||||||||||||||||||||||
|
Nonqualified |
||||||||||||||||||||||||||||||||
|
Non-Equity |
Deferred |
|||||||||||||||||||||||||||||||
|
Stock |
Option |
Incentive Plan |
Compensation |
All Other |
||||||||||||||||||||||||||||
|
Salary |
Awards(1) |
Awards(2) |
Compensation(3) |
Earnings(4) |
Compensation(5) |
|||||||||||||||||||||||||||
| Name and Principal Position | Year | ($) | ($) | ($) | ($) | ($) | ($) | Total | ||||||||||||||||||||||||
| (a) | (b) | (c) | (e) | (f) | (g) | (h) | (i) | (j) | ||||||||||||||||||||||||
|
David C. Dvorak
|
2010 | 833,654 | 3,637,854 | 3,421,600 | 1,039,475 | 582,300 | 40,327 | 9,555,210 | ||||||||||||||||||||||||
|
President and
|
2009 | 787,067 | 1,542,083 | 3,565,427 | 831,812 | 316,132 | 40,631 | 7,083,152 | ||||||||||||||||||||||||
|
Chief Executive Officer
|
2008 | 742,308 | | 4,754,000 | 691,350 | 239,814 | 38,977 | 6,466,449 | ||||||||||||||||||||||||
|
James T. Crines
|
2010 | 489,331 | 1,311,252 | 1,235,780 | 404,739 | 486,406 | 25,387 | 3,952,895 | ||||||||||||||||||||||||
|
Executive Vice President,
|
2009 | 475,083 | 538,951 | 1,247,179 | 327,451 | 288,850 | 26,937 | 2,904,451 | ||||||||||||||||||||||||
|
Finance and Chief
|
2008 | 456,340 | | 1,671,525 | 274,078 | 236,777 | 26,193 | 2,664,913 | ||||||||||||||||||||||||
|
Financial Officer
|
||||||||||||||||||||||||||||||||
|
Bruno A. Melzi
|
2010 | 563,026 | (6) | 1,125,588 | 1,059,240 | 426,016 | (6) | 83,843 | (6) | 121,394 | (6) | 3,379,107 | ||||||||||||||||||||
|
Chairman, Europe,
|
2009 | 577,538 | (6) | 462,625 | 1,069,468 | 344,992 | (6) | 73,764 | (6) | 83,947 | (6) | 2,612,334 | ||||||||||||||||||||
|
Middle East and Africa
|
2008 | 586,114 | (6) | | 1,231,650 | 301,731 | (6) | 75,281 | (6) | 206,113 | (6) | 2,400,889 | ||||||||||||||||||||
|
Jeffery A. McCaulley
|
2010 | 510,191 | 1,125,588 | 1,059,240 | 415,890 | | 122,382 | 3,233,291 | ||||||||||||||||||||||||
|
President, Zimmer
|
2009 | 500,000 | 462,625 | 1,069,468 | 321,650 | | 285,524 | 2,639,267 | ||||||||||||||||||||||||
|
Reconstructive
|
||||||||||||||||||||||||||||||||
|
Jeffrey B. Paulsen
|
2010 | 465,000 | 1,393,508 | 1,304,940 | 341,319 | | 584,610 | 4,089,377 | ||||||||||||||||||||||||
|
Group President,
Global Businesses |
||||||||||||||||||||||||||||||||
| (1) | Represents the grant date fair value of stock awards determined in accordance with ASC 718. For a discussion of the assumptions made in the valuation of the stock awards, see Note 3 to the Consolidated Financial Statements included in our Annual Reports on Form 10-K for the years ended December 31, 2010 and December 31, 2009. The 2010 stock awards consist of performance-based RSUs and, with respect to Mr. Paulsen, a grant of time-based RSUs. The 2009 stock awards consist of performance-based RSUs. Performance-based RSU amounts represent the value at the grant date based upon the probable outcome of the performance conditions. The following table presents the grant date fair value of the performance-based RSUs included in the Stock Awards column for 2010 and 2009 and the grant date fair value of these awards assuming that the highest level of performance conditions would be achieved: |
| 2010 Performance-Based RSU Awards | 2009 Performance-Based RSU Awards | |||||||||||||||
|
Grant Date Fair Value |
Grant Date Fair Value |
Grant Date Fair Value |
Grant Date Fair Value |
|||||||||||||
|
(Based on Probable |
(Based on Maximum |
(Based on Probable |
(Based on Maximum |
|||||||||||||
|
Name
|
Outcome) ($) | Performance) ($) | Outcome) ($) | Performance) ($) | ||||||||||||
|
David C. Dvorak
|
3,637,854 | 5,456,781 | 1,542,083 | 2,570,139 | ||||||||||||
|
James T. Crines
|
1,311,252 | 1,966,878 | 538,951 | 898,251 | ||||||||||||
|
Bruno A. Melzi
|
1,125,588 | 1,688,382 | 462,625 | 771,042 | ||||||||||||
|
Jeffery A. McCaulley
|
1,125,588 | 1,688,382 | 462,625 | 771,042 | ||||||||||||
|
Jeffrey B. Paulsen
|
893,508 | 1,340,262 | | | ||||||||||||
| (2) | Represents the grant date fair value of option awards determined in accordance with ASC 718. For a discussion of the assumptions made in the valuation of our stock options, see Note 3 to the Consolidated Financial Statements included in our Annual Reports on Form 10-K for the years ended December 31, 2010, December 31, 2009 and December 31, 2008. | |
| (3) | Amounts reported consist solely of awards made under the EPIP. We provide more information regarding the EPIP above under Compensation Discussion and Analysis Executive Compensation for 2010 Annual Cash Incentives. | |
| (4) | Amounts reported consist of the following: |
|
RIP Aggregate |
BEP/RIP Aggregate |
Aggregate Change in |
||||||||||||||
|
Change in Actuarial |
Change in Actuarial |
Actuarial Present Value of |
||||||||||||||
|
Present Value of |
Present Value of |
Accumulated Benefit under |
||||||||||||||
|
Accumulated |
Accumulated |
Trattamento Fine Rapporto, |
||||||||||||||
|
Name
|
Benefit($)(a) | Benefit($)(a) | an Italian pension plan($) | Total($) | ||||||||||||
|
David C. Dvorak
|
||||||||||||||||
|
2010
|
57,889 | 524,411 | | 582,300 | ||||||||||||
|
2009
|
19,114 | 297,018 | | 316,132 | ||||||||||||
|
2008
|
40,345 | 199,469 | | 239,814 | ||||||||||||
|
James T. Crines
|
||||||||||||||||
|
2010
|
82,546 | 403,860 | | 486,406 | ||||||||||||
|
2009
|
33,277 | 255,573 | | 288,850 | ||||||||||||
|
2008
|
57,997 | 178,780 | | 236,777 | ||||||||||||
|
Bruno A. Melzi
|
||||||||||||||||
|
2010
|
| | 83,843 | (b) | 83,843 | (b) | ||||||||||
|
2009
|
| | 73,764 | (c) | 73,764 | (c) | ||||||||||
|
2008
|
| | 75,281 | (d) | 75,281 | (d) | ||||||||||
|
Jeffery A.
McCaulley(e)
|
||||||||||||||||
|
2010
|
| | | | ||||||||||||
|
2009
|
| | | | ||||||||||||
|
Jeffrey B.
Paulsen(e)
|
||||||||||||||||
|
2010
|
| | | | ||||||||||||
| (a) | Amounts represent the change in the actuarial present value of the accumulated benefit under the RIP and the BEP/RIP from December 31, 2009 to December 31, 2010, December 31, 2008 to December 31, 2009, and from December 31, 2007 to December 31, 2008, respectively. The accumulated benefit is the benefit to which the executive would be entitled had he terminated employment as of December 31 of such year and elected to commence his benefit at the earliest age at which he would receive an unreduced benefit, assuming he had met the eligibility conditions, payable as a monthly benefit for as long as the executive lived. The expected benefit payments are discounted using interest and mortality assumptions to produce the present value of the accumulated benefit as of December 31 of such year. With respect to the RIP, the assumed interest rates for 2010, 2009 and 2008 are 5.82%, 6.26% and 5.79%, respectively, and the mortality assumption for each year is based on the 1994 Group Annuity Mortality Tables for men and women. With respect to the BEP/RIP, the assumed interest rates are 1.98% for the first 5 years, 5.23% for the next 15 years and 6.52% for years above 20 and the mortality assumption is based on the 2011 IRS mortality table. | |
| (b) | Amount represents the increase in the actuarial present value of the accumulated benefit from December 31, 2009 to December 31, 2010 calculated in Euros for the period, with the difference converted to U.S. Dollars using the average exchange rate for 2010 of 1 EUR = 1.32928 USD. | |
| (c) | Amount represents the increase in the actuarial present value of the accumulated benefit from December 31, 2008 to December 31, 2009 calculated in Euros for the period, with the difference converted to U.S. Dollars using the average exchange rate for 2009 of 1 EUR = 1.3930 USD. | |
| (d) | Amount represents the increase in the actuarial present value of the accumulated benefit from December 31, 2007 to December 31, 2008 calculated in Euros for the period, with the difference converted to U.S. Dollars using the average exchange rate for 2008 of 1 EUR = 1.47154 USD. | |
| (e) | Messrs. McCaulley and Paulsen are not eligible to participate in our defined benefit pension plans. |
| (5) | Amounts reported for 2010 consist of the following: |
| Mr. Dvorak | Mr. Crines | Mr. Melzi(6) | Mr. McCaulley | Mr. Paulsen | ||||||||||||||||
|
Company contributions to the SIP
|
$ | 11,025 | $ | 11,025 | $ | | $ | 19,600 | $ | 12,661 | ||||||||||
|
Company contributions to the BEP/SIP
|
26,489 | 10,995 | | 1,254 | | |||||||||||||||
|
Company-paid long-term disability insurance premiums
|
2,813 | 3,367 | | 3,143 | 1,317 | |||||||||||||||
|
Relocation assistance
|
| | | 98,385 | (a) | 326,632 | (b) | |||||||||||||
|
Bonus loss reimbursement
|
| | | | 244,000 | (c) | ||||||||||||||
|
Holiday and unused vacation pay
|
| | 13,690 | | | |||||||||||||||
|
Company-paid supplemental health insurance premiums and claims
|
| | 2,133 | | | |||||||||||||||
|
Annual medical
check-up
|
| | 1,210 | | | |||||||||||||||
|
Payment in lieu of company contribution to National Pension
Authority pursuant to Italian law
|
| | 61,506 | | | |||||||||||||||
|
Company contributions to Fondo Mario Negri, an Italian pension
plan
|
| | 10,996 | | | |||||||||||||||
|
Incremental cost of company-provided automobile
|
| | 31,859 | | | |||||||||||||||
|
Total
|
$ | 40,327 | $ | 25,387 | $ | 121,394 | $ | 122,382 | $ | 584,610 | ||||||||||
| (a) | This amount includes the cost of relocation benefits provided to Mr. McCaulley of $65,683 and a tax gross-up of $32,702, consistent with our relocation assistance program for U.S.-based management-level employees. To the extent reimbursement of moving expenses, temporary living expenses and other relocation assistance is taxable to the recipient, we may provide a cash payment to the recipient to offset the tax payable on such reimbursement, in whole or in part. The tax reimbursement feature of our relocation assistance program is generally available to all U.S.-based management-level employees. | |
| (b) | This amount includes the cost of relocation benefits provided to Mr. Paulsen of $157,818 and a tax gross-up of $18,814, consistent with our relocation assistance program for U.S.-based management-level employees. Mr. Paulsen must repay a pro-rata portion of the relocation benefits to us in the event he voluntarily resigns or is terminated for cause within one year of receipt of the benefits. This amount also includes a special loss-on-sale benefit of $150,000 to compensate Mr. Paulsen for a portion of the loss he incurred on the sale of his principal residence. Mr. Paulsen did not receive tax gross-up assistance related to this payment and is responsible for all applicable taxes. Mr. Paulsen must repay this loss-on-sale benefit to us in the event he voluntarily resigns or is terminated for cause within two years of receipt of the benefit. We provide additional information on the loss-on-sale benefit above under Compensation Discussion and Analysis Executive Compensation for 2010 Other Compensation Perquisites. | |
| (c) | This amount represents a bonus loss reimbursement benefit provided to Mr. Paulsen to facilitate his hiring and to mitigate the financial loss associated with his forfeiting the bonus he otherwise would have received from his former employer for the period January 1, 2009 through his date of termination to join Zimmer. The committee approved this benefit after consultation with Towers Watson and as part of the negotiation of Mr. Paulsens compensation package. We did not provide Mr. Paulsen with tax gross-up assistance related to this payment and he is responsible for all applicable taxes. Mr. Paulsen must repay this bonus loss reimbursement benefit to us in the event he voluntarily resigns or is terminated for cause within one year of receipt of the benefit. We provide additional information on the bonus loss reimbursement benefit above under Compensation Discussion and Analysis Executive Compensation for 2010 Other Compensation Perquisites. |
| (6) | Mr. Melzis compensation is paid in Euros and has been converted to U.S. Dollars for purposes of this table (a) for 2010 compensation, using the average exchange rate for 2010 of 1 EUR = 1.32928 USD; (b) for 2009 compensation, using the average exchange rate for 2009 of 1 EUR = 1.3930 USD, and (c) for 2008 compensation, using the average exchange rate for 2008 of 1 EUR = 1.47154 USD. |
|
All Other |
All Other |
Grant |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stock |
Option |
Date |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Awards: |
Awards: |
Exercise |
Closing |
Fair Value |
||||||||||||||||||||||||||||||||||||||||||||||||
|
Number of |
Number of |
or Base |
Market |
of Stock |
||||||||||||||||||||||||||||||||||||||||||||||||
|
Date |
Estimated Possible Payouts Under |
Estimated Possible Payouts Under |
Shares of |
Securities |
Price of |
Price on |
and |
|||||||||||||||||||||||||||||||||||||||||||||
|
of Comp. |
Non-Equity Incentive Plan Awards | Equity Incentive Plan Awards |
Stocks or |
Underlying |
Option |
Date of |
Option |
|||||||||||||||||||||||||||||||||||||||||||||
|
Grant |
Committee |
Threshold |
Target |
Maximum |
Threshold |
Target |
Maximum |
Units |
Options |
Awards(1) |
Grant |
Awards(2) |
||||||||||||||||||||||||||||||||||||||||
|
Name
|
Date | Action | ($) | ($) | ($) | (#) | (#) | (#) | (#) | (#) | ($/Sh) | ($/Sh) | ($) | |||||||||||||||||||||||||||||||||||||||
| (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | (k) | (l) | |||||||||||||||||||||||||||||||||||||||||
|
David C. Dvorak
|
| | 495,650 | 991,299 | 1,982,598 | | | | | | | | | |||||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | 31,350 | 62,700 | 94,050 | | | | | 3,637,854 | ||||||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | | | | | 188,000 | 58.02 | 57.81 | 3,421,600 | ||||||||||||||||||||||||||||||||||||||||
|
James T. Crines
|
| | 192,991 | 385,981 | 771,962 | | | | | | | | | |||||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | 11,300 | 22,600 | 33,900 | | | | | 1,311,252 | ||||||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | | | | | 67,900 | 58.02 | 57.81 | 1,235,780 | ||||||||||||||||||||||||||||||||||||||||
|
Bruno A. Melzi
|
| | 205,230 | (3) | 410,460 | (3) | 820,921 | (3) | | | | | | | | | ||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | 9,700 | 19,400 | 29,100 | | | | | 1,125,588 | ||||||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | | | | | 58,200 | 58.02 | 57.81 | 1,059,240 | ||||||||||||||||||||||||||||||||||||||||
|
Jeffery A. McCaulley
|
| | 198,306 | 396,615 | 793,230 | | | | | | | | | |||||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | 9,700 | 19,400 | 29,100 | | | | | 1,125,588 | ||||||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | | | | | 58,200 | 58.02 | 57.81 | 1,059,240 | ||||||||||||||||||||||||||||||||||||||||
|
Jeffrey B. Paulsen
|
| | 162,750 | 325,500 | 651,000 | | | | | | | | | |||||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | 7,700 | 15,400 | 23,100 | | | | | 893,508 | ||||||||||||||||||||||||||||||||||||||||
| 03/16/10 | 02/12/10 | | | | | | | | 46,200 | 58.02 | 57.81 | 840,840 | ||||||||||||||||||||||||||||||||||||||||
| 01/04/10 | 12/11/09 | | | | | | | | 25,500 | 59.73 | 60.02 | 464,100 | ||||||||||||||||||||||||||||||||||||||||
| 01/04/10 | 12/11/09 | | | | | | | 8,371 | | | | 500,000 | ||||||||||||||||||||||||||||||||||||||||
| (1) | The committee set the exercise price of stock options at fair market value on the date of grant. The 2009 Plan defines fair market value as the average of the high and low selling prices of our common stock on the New York Stock Exchange on the date of grant. An exercise price in excess of fair market value may be used for employees based outside the United States. | |
| (2) | Amounts represent the grant date fair value of stock and option awards determined in accordance with ASC 718. With respect to equity incentive plan awards, amounts represent the value at the grant date of performance-based RSUs based upon the probable outcome of the performance conditions. For a discussion of the assumptions made in the valuation of our equity awards, see Note 3 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2010. | |
| (3) | Mr. Melzis compensation is paid in Euros and has been converted to U.S. Dollars for purposes of this table using the average exchange rate for 2010 of 1 EUR = 1.32928 USD. |
|
Actual number |
||||
|
Name
|
of RSUs earned | |||
|
David C. Dvorak
|
63,691 | |||
|
James T. Crines
|
22,957 | |||
|
Bruno A. Melzi
|
19,707 | |||
|
Jeffery A. McCaulley
|
19,707 | |||
|
Jeffrey B. Paulsen
|
15,643 | |||
| Option Awards(1) | Stock Awards | |||||||||||||||||||||||||||
|
Number of |
Number of |
Number of |
Market Value |
|||||||||||||||||||||||||
|
Securities |
Securities |
Shares or |
of Shares or |
|||||||||||||||||||||||||
|
Underlying |
Underlying |
Units of |
Units of |
|||||||||||||||||||||||||
|
Unexercised |
Unexercised |
Option |
Stock That |
Stock That |
||||||||||||||||||||||||
|
Options |
Options |
Exercise |
Option |
Have Not |
Have Not |
|||||||||||||||||||||||
|
(#) |
(#) |
Price(2) |
Expiration |
Vested(3) |
Vested(4) |
|||||||||||||||||||||||
|
Name
|
Grant Date | Exercisable | Unexercisable |
($)
|
Date | (#) |
($)
|
|||||||||||||||||||||
| (a) | (b) | (c) | (e) | (f) | (g) | (h) | ||||||||||||||||||||||
|
David C. Dvorak
|
03/16/2010 | | 188,000 | 58.02 | 03/15/2020 | |||||||||||||||||||||||
| 02/17/2009 | 55,675 | 167,025 | 39.94 | 02/16/2019 | ||||||||||||||||||||||||
| 02/19/2008 | 100,000 | 100,000 | 76.33 | 02/18/2018 | ||||||||||||||||||||||||
| 05/01/2007 | 75,000 | 25,000 | 88.76 | 04/30/2017 | ||||||||||||||||||||||||
| 02/06/2007 | 39,375 | 13,125 | 83.68 | 02/05/2017 | ||||||||||||||||||||||||
| 01/18/2006 | 55,000 | | 71.06 | 01/17/2016 | ||||||||||||||||||||||||
| 01/18/2005 | 23,408 | | 79.60 | 01/17/2015 | ||||||||||||||||||||||||
| 01/18/2005 | 34,833 | | 79.60 | 01/17/2015 | ||||||||||||||||||||||||
| 01/14/2004 | 73,333 | | 70.33 | 01/13/2014 | ||||||||||||||||||||||||
| 01/13/2003 | 66,000 | | 39.53 | 01/12/2013 | ||||||||||||||||||||||||
| 01/02/2002 | 50,000 | | 30.19 | 01/01/2012 | ||||||||||||||||||||||||
| 12/03/2001 | 34,635 | | 32.21 | 12/02/2011 | ||||||||||||||||||||||||
| 03/16/2010 | 63,691 | 3,418,933 | ||||||||||||||||||||||||||
| 02/17/2009 | 41,905 | 2,249,460 | ||||||||||||||||||||||||||
| 05/01/2007 | 15,022 | 806,381 | ||||||||||||||||||||||||||
|
James T. Crines
|
03/16/2010 | | 67,900 | 58.02 | 03/15/2020 | |||||||||||||||||||||||
| 02/17/2009 | 19,475 | 58,425 | 39.94 | 02/16/2019 | ||||||||||||||||||||||||
| 02/12/2008 | 35,625 | 35,625 | 78.53 | 02/11/2018 | ||||||||||||||||||||||||
| 05/01/2007 | 18,750 | 6,250 | 88.76 | 04/30/2017 | ||||||||||||||||||||||||
| 02/06/2007 | 28,125 | 9,375 | 83.68 | 02/05/2017 | ||||||||||||||||||||||||
| 01/18/2006 | 51,000 | | 71.06 | 01/17/2016 | ||||||||||||||||||||||||
| 01/18/2005 | 16,385 | | 79.60 | 01/17/2015 | ||||||||||||||||||||||||
| 01/18/2005 | 24,383 | | 79.60 | 01/17/2015 | ||||||||||||||||||||||||
| 01/14/2004 | 46,200 | | 70.33 | 01/13/2014 | ||||||||||||||||||||||||
| 01/13/2003 | 14,569 | | 39.53 | 01/12/2013 | ||||||||||||||||||||||||
| 01/02/2002 | 15,000 | | 30.19 | 01/01/2012 | ||||||||||||||||||||||||
| 01/02/2002 | 5,000 | | 30.19 | 01/01/2012 | ||||||||||||||||||||||||
| 03/16/2010 | 22,957 | 1,232,332 | ||||||||||||||||||||||||||
| 02/17/2009 | 14,646 | 786,197 | ||||||||||||||||||||||||||
| 05/01/2007 | 7,510 | 403,137 | ||||||||||||||||||||||||||
|
Bruno A. Melzi
|
03/16/2010 | | 58,200 | 58.02 | 03/15/2020 | |||||||||||||||||||||||
| 02/17/2009 | 50,000 | | 39.94 | 02/16/2019 | ||||||||||||||||||||||||
| 02/12/2008 | 52,500 | | 78.53 | 02/11/2018 | ||||||||||||||||||||||||
| 02/06/2007 | 39,375 | 13,125 | 83.68 | 02/05/2017 | ||||||||||||||||||||||||
| 01/18/2006 | 57,000 | | 71.06 | 01/17/2016 | ||||||||||||||||||||||||
| 01/18/2005 | 25,536 | | 79.60 | 01/17/2015 | ||||||||||||||||||||||||
| 01/18/2005 | 38,000 | | 79.60 | 01/17/2015 | ||||||||||||||||||||||||
| 03/16/2010 | 19,707 | 1,057,872 | ||||||||||||||||||||||||||
| 02/17/2009 | 12,571 | 674,811 | ||||||||||||||||||||||||||
|
Jeffery A. McCaulley
|
03/16/2010 | | 58,200 | 58.02 | 03/15/2020 | |||||||||||||||||||||||
| 02/17/2009 | 16,700 | 50,100 | 39.94 | 02/16/2019 | ||||||||||||||||||||||||
| 12/01/2008 | 22,728 | 22,727 | 36.19 | 11/30/2018 | ||||||||||||||||||||||||
| 03/16/2010 | 19,707 | 1,057,872 | ||||||||||||||||||||||||||
| 02/17/2009 | 12,571 | 674,811 | ||||||||||||||||||||||||||
| 12/01/2008 | 17,270 | 927,054 | ||||||||||||||||||||||||||
|
Jeffrey B. Paulsen
|
03/16/2010 | | 46,200 | 58.02 | 03/15/2020 | |||||||||||||||||||||||
| 01/04/2010 | 6,375 | 19,125 | 59.73 | 01/03/2020 | ||||||||||||||||||||||||
| 03/16/2010 | 15,643 | 839,716 | ||||||||||||||||||||||||||
| 01/04/2010 | 8,371 | 449,355 | ||||||||||||||||||||||||||
| (1) | Stock options become exercisable in accordance with the following vesting schedule. Option awards may vest on an accelerated basis after the executive has held the award for at least one year if the executive reaches age 60 or retires. |
|
Grant Date
|
Vesting
|
|
|
03/16/2010
|
25% per year beginning on the first anniversary of the grant date
|
|
|
01/04/2010
|
25% per year beginning on the first anniversary of the grant date
|
|
|
02/17/2009
|
25% per year beginning on the first anniversary of the grant date
|
|
|
12/01/2008
|
25% per year beginning on the first anniversary of the grant date
|
|
|
02/19/2008
|
25% per year beginning on the first anniversary of the grant date
|
|
|
02/12/2008
|
25% per year beginning on the first anniversary of the grant date
|
|
|
05/01/2007
|
25% per year beginning on the first anniversary of the grant date
|
|
|
02/06/2007
|
25% per year beginning on the first anniversary of the grant
date, except that, with respect to Mr. Melzi, 75% became
exercisable on the third anniversary of the grant date and 25%
will become exercisable on the fourth anniversary, pursuant to
Italian law
|
|
|
01/18/2006
|
25% per year beginning on the first anniversary of the grant date
|
|
|
01/18/2005
|
25% became exercisable on 02/17/2006 following certification of
our achievement of performance measures based on 2005
performance; the remaining 75% became exercisable ratably on the
second through fourth anniversaries of the grant date
|
|
|
01/18/2005
|
25% per year beginning on the first anniversary of the grant date
|
|
|
01/14/2004
|
25% per year beginning on the first anniversary of the grant date
|
|
|
01/13/2003
|
25% per year beginning on the first anniversary of the grant date
|
|
|
01/02/2002
|
25% per year beginning on the first anniversary of the grant date
|
|
|
12/03/2001
|
25% per year beginning on the first anniversary of the grant date
|
| (2) | The option exercise price is equal to the average of the high and low selling prices of our common stock as reported by the New York Stock Exchange on the date of grant. | |
| (3) | Restricted stock, RSUs and performance-based RSUs vest in accordance with the following schedule. |
|
Grant Date
|
Type of Award
|
Vesting
|
||
|
03/16/2010
|
Performance-based RSUs |
331/3%
per year beginning on the second anniversary of the grant date,
contingent upon 2010 performance
|
||
|
01/04/2010
|
RSUs |
331/3%
per year beginning on the third anniversary of the grant date
|
||
|
02/17/2009
|
Performance-based RSUs |
331/3%
per year beginning on the second anniversary of the grant date,
contingent upon 2009 performance
|
||
|
12/01/2008
|
Restricted Stock |
331/3%
per year beginning on the third anniversary of the grant date
|
||
|
05/01/2007
|
Restricted Stock |
331/3%
per year beginning on the third anniversary of the grant date
|
| (4) | Market value is calculated by multiplying the number of shares in column (g) by $53.68, the closing price of our common stock as reported by the New York Stock Exchange on December 31, 2010. |
| Option Awards | Stock Awards | |||||||
|
Number of Shares |
Value Realized |
Number of Shares |
Value Realized |
|||||
|
Acquired on Exercise |
On Exercise |
Acquired on Vesting |
on Vesting |
|||||
|
Name
|
(#) | ($)(1) | (#) | ($)(2) | ||||
| (a) | (b) | (c) | (d) | (e) | ||||
|
David C. Dvorak
|
| | 7,510 | 457,434 | ||||
|
James T. Crines
|
| | 3,756 | 228,778 | ||||
|
Bruno A. Melzi
|
16,800 | 195,888 | | | ||||
|
Jeffery A. McCaulley
|
| | | | ||||
|
Jeffrey B. Paulsen
|
| | | | ||||
| (1) | Value realized is calculated on the basis of the difference between the exercise price and the closing price of our common stock as reported by the New York Stock Exchange on the date of exercise, multiplied by the number of shares of common stock underlying the options exercised. | |
| (2) | Value realized is calculated by multiplying the closing price of our common stock on the New York Stock Exchange on the date of vesting by the number of shares of common stock that vested. |
|
Number of |
Present Value |
|||||||||
|
Years |
of |
|||||||||
|
Credited |
Accumulated |
|||||||||
|
Service |
Benefit(2) |
|||||||||
|
Name
|
Plan Name(1) | (#) | ($) | |||||||
| (a) | (b) | (c) | (d) | |||||||
|
David C. Dvorak
|
RIP | 9.135 | 224,247 | |||||||
| BEP/RIP | 9.135 | 1,310,611 | ||||||||
|
James T. Crines
|
RIP | 15.387 | 343,861 | |||||||
| BEP/RIP | 15.387 | 1,156,358 | ||||||||
|
Bruno A. Melzi
|
Trattamento Fine Rapporto | 20.817 | 877,952 | (3) | ||||||
|
Jeffery A.
McCaulley(4)
|
N/A | | | |||||||
|
Jeffrey B.
Paulsen(4)
|
N/A | | | |||||||
| (1) | The full name of the plan referred to as the RIP in the table is the Zimmer Holdings, Inc. Retirement Income Plan. The full name of the plan referred to as the BEP/RIP in the table is the Benefit Equalization Plan of Zimmer Holdings, Inc. and its Subsidiary or Affiliated Corporations Participating in the Zimmer Holdings, Inc. Retirement Income Plan or the Zimmer Puerto Rico Retirement Income Plan. | |
| (2) | The accumulated benefit is the benefit to which the executive would be entitled had he terminated employment on December 31, 2010 and elected to commence his benefit at the earliest age at which he would receive an unreduced benefit, assuming he had met the eligibility conditions, payable as a monthly benefit for as long as the executive lived. The expected benefit payments are discounted using interest and mortality assumptions to produce the present value of the accumulated benefit as of December 31, 2010. With respect to the RIP, the assumed interest rate is 5.82% and the mortality assumption is based on the 1994 Group Annuity Mortality Tables for men and women. With respect to the BEP/RIP, the assumed interest rates are 1.98% for the first 5 years, 5.23% for the next 15 years and 6.52% for years above 20 and the mortality assumption is based on the 2011 IRS mortality table. | |
| (3) | Mr. Melzis compensation is paid in Euros and has been converted to U.S. Dollars for purposes of this table using the average exchange rate for 2010 of 1 EUR = 1.32928 USD. | |
| (4) | Messrs. McCaulley and Paulsen are not eligible to participate in our defined benefit pension plans. |
| | Final average compensation which is equal to the average of the highest five consecutive years of pension compensation during the 10 years immediately prior to the executives date of termination. |
| | Pension compensation is equal to the executives annualized base salary plus regular incentive award payments received during the year. |
| | Pension compensation is limited to $245,000 for 2010 and 2011. This limit increases annually by inflation. |
| | Years of service include service earned while an employee of our former parent company. Service is capped at 40 years. |
| | Estimated Social Security benefit payable at age 65. |
| | Value of retirement benefits that will be paid from our former parent companys retirement plan. |
|
Retirement |
5 or More Years of |
|||||||
|
Age
|
Service But Less Than 10 | 10 or More Years of Service | ||||||
|
65
|
0 | % | 0 | % | ||||
|
64
|
10 | % | 0 | % | ||||
|
63
|
18 | % | 0 | % | ||||
|
62
|
26 | % | 0 | % | ||||
|
61
|
32 | % | 0 | % | ||||
|
60
|
38 | % | 0 | % | ||||
|
59
|
44 | % | 4 | % | ||||
|
58
|
49 | % | 8 | % | ||||
|
57
|
53 | % | 12 | % | ||||
|
56
|
57 | % | 16 | % | ||||
|
55
|
61 | % | 20 | % | ||||
| | Limitation on compensation is ignored. |
| | 40 year service limitation is ignored. |
| | Regular incentive award payments paid during the year are replaced by regular incentive award payments earned during the year. |
| | An executive will receive a lump sum payment of his or her entire benefit. In accordance with Section 409A of the Code, payments are delayed six months from the date of separation from service. |
|
Executive |
Registrant |
Aggregate |
Aggregate |
|||||||||||||
|
Contributions |
Contributions |
Earnings |
Balance at |
|||||||||||||
|
in Last FY |
in Last FY |
in Last FY |
Last FYE |
|||||||||||||
|
Name
|
($)(1) | ($)(2) | ($)(3) | ($)(4) | ||||||||||||
| (a) | (b) | (c) | (d) | (f) | ||||||||||||
|
David C. Dvorak
|
878,519 | 26,489 | 399,165 | 4,406,820 | ||||||||||||
|
James T. Crines
|
24,433 | 10,995 | 1,738 | 138,204 | ||||||||||||
|
Bruno A. Melzi
|
| | | | ||||||||||||
|
Jeffery A. McCaulley
|
| 1,254 | 32 | 1,286 | ||||||||||||
|
Jeffrey B. Paulsen
|
| | | | ||||||||||||
| (1) | Amounts shown in this column are or were previously reported in the Summary Compensation Table, as follows: |
|
Amount Reported as |
||||||||
|
Amount Reported as Salary |
Non-Equity Incentive |
|||||||
|
in the Summary Compensation |
Compensation in the Summary |
|||||||
|
Table of this Proxy |
Compensation |
|||||||
|
Statement |
Table of 2009 Proxy Statement |
|||||||
| ($) | ($) | |||||||
|
Mr. Dvorak
|
88,298 | 790,221 | ||||||
|
Mr. Crines
|
24,433 | | ||||||
|
Mr. Melzi
|
| | ||||||
|
Mr. McCaulley
|
| | ||||||
|
Mr. Paulsen
|
| | ||||||
| (2) | The amounts shown in this column are reported in the Summary Compensation Table as part of All Other Compensation. | |
| (3) | The amounts shown in this column are not reported as compensation in the Summary Compensation Table as they do not represent above-market or preferential earnings on deferred compensation. |
| (4) | Of the amounts shown in this column, the following amounts are or were previously reported in the Summary Compensation Table: |
|
Aggregate Amount Reported in |
||||
|
the Summary Compensation |
||||
|
Table of this and prior Proxy |
||||
|
Statements |
||||
| ($) | ||||
|
Mr. Dvorak
|
3,769,909 | |||
|
Mr. Crines
|
124,363 | |||
|
Mr. Melzi
|
| |||
|
Mr. McCaulley
|
1,254 | |||
|
Mr. Paulsen
|
| |||
| Termination Scenario | ||||||||||||||||||||||||||||
|
Company- |
Company- |
|||||||||||||||||||||||||||
|
Initiated |
Initiated |
|||||||||||||||||||||||||||
|
Change in |
Voluntary |
(with |
(without |
|||||||||||||||||||||||||
|
Compensation Components
|
Control($) | Resignation($) | Retirement($) | Death($) | Disability($) | Cause)($) | Cause)($) | |||||||||||||||||||||
|
David C. Dvorak
|
||||||||||||||||||||||||||||
|
Severance
Salary(1)
|
1,700,000 | | | | | | | |||||||||||||||||||||
|
Severance EPIP
Award(2)
|
2,040,000 | | | | | | | |||||||||||||||||||||
|
2010 EPIP
Award(3)
|
1,020,000 | | | 1,039,475 | 1,039,475 | | | |||||||||||||||||||||
|
Stock
Options(4)
|
5,911,911 | 3,616,988 | 3,616,988 | 5,911,911 | 5,911,911 | 3,616,988 | 5,911,911 | |||||||||||||||||||||
|
Restricted
Stock(5)
|
806,381 | | | 806,381 | 806,381 | | 235,222 | |||||||||||||||||||||
|
RSUs(6)
|
5,668,393 | | | 2,249,460 | 2,249,460 | | 624,855 | |||||||||||||||||||||
|
RIP(7)
|
150,277 | 150,277 | 150,277 | 123,176 | 150,277 | 150,277 | 150,277 | |||||||||||||||||||||
|
Nonqual. Pension & Def. Comp.
|
||||||||||||||||||||||||||||
|
BEP/RIP(8)
|
1,505,873 | 774,472 | 774,472 | 670,677 | 774,472 | 774,472 | 774,472 | |||||||||||||||||||||
|
BEP/SIP(9)
|
637,875 | 637,875 | 637,875 | 637,875 | 637,875 | 637,875 | 637,875 | |||||||||||||||||||||
|
EPIP(10)
|
3,768,945 | 3,768,945 | 3,768,945 | 3,768,945 | 3,768,945 | 3,768,945 | 3,768,945 | |||||||||||||||||||||
|
Health and
Welfare(11)
|
59,278 | | | | | | | |||||||||||||||||||||
|
Disability(12)
|
| | | | 7,755,979 | | | |||||||||||||||||||||
|
Outplacement(13)
|
25,000 | | | |||||||||||||||||||||||||
|
Gross-up(14)
|
3,112,863 | | | | | | | |||||||||||||||||||||
|
James T. Crines
|
||||||||||||||||||||||||||||
|
Severance
Salary(1)
|
988,600 | | | | | | | |||||||||||||||||||||
|
Severance EPIP
Award(2)
|
790,880 | | | | | | | |||||||||||||||||||||
|
2010 EPIP
Award(3)
|
395,440 | | | 404,739 | 404,739 | | | |||||||||||||||||||||
|
Stock
Options(4)
|
1,746,297 | 943,538 | 943,538 | 1,746,297 | 1,746,297 | 943,538 | 1,746,297 | |||||||||||||||||||||
|
Restricted
Stock(5)
|
403,137 | | | 403,137 | 403,137 | | 117,558 | |||||||||||||||||||||
|
RSUs(6)
|
2,018,529 | | | 786,197 | 786,197 | | 218,390 | |||||||||||||||||||||
|
RIP(7)
|
230,436 | 230,436 | 230,436 | 208,749 | 230,436 | 230,436 | 230,436 | |||||||||||||||||||||
|
Nonqual. Pension & Def. Comp.
|
||||||||||||||||||||||||||||
|
BEP/RIP(8)
|
1,277,354 | 724,539 | 724,539 | 654,176 | 724,539 | 724,539 | 724,539 | |||||||||||||||||||||
|
BEP/SIP(9)
|
138,204 | 138,204 | 138,204 | 138,204 | 138,204 | 138,204 | 138,204 | |||||||||||||||||||||
|
Health and
Welfare(11)
|
39,490 | | | | | | | |||||||||||||||||||||
|
Disability(12)
|
| | | | 2,452,428 | | | |||||||||||||||||||||
|
Outplacement(13)
|
25,000 | | | | | | | |||||||||||||||||||||
| Termination Scenario | ||||||||||||||||||||||||||||
|
Company- |
Company- |
|||||||||||||||||||||||||||
|
Initiated |
Initiated |
|||||||||||||||||||||||||||
|
Change in |
Voluntary |
(with |
(without |
|||||||||||||||||||||||||
|
Compensation Components
|
Control($) | Resignation($) | Retirement($) | Death($) | Disability($) | Cause)($) | Cause)($) | |||||||||||||||||||||
|
Bruno A. Melzi
|
||||||||||||||||||||||||||||
|
Severance
Salary(1)
|
1,132,546 | | | | | | | |||||||||||||||||||||
|
Severance EPIP
Award(2)
|
849,410 | | | | | | | |||||||||||||||||||||
|
2010 EPIP
Award(3)
|
424,705 | | 426,016 | 426,016 | 426,016 | | | |||||||||||||||||||||
|
Stock Options
|
687,000 | 687,000 | 687,000 | 687,000 | 687,000 | 687,000 | 687,000 | |||||||||||||||||||||
|
RSUs(6)
|
1,732,683 | 674,811 | 674,811 | 674,811 | 674,811 | | 674,811 | |||||||||||||||||||||
|
Non-U.S.
Pension Plans
|
||||||||||||||||||||||||||||
|
Trattamento Fine
Rapporto(15)
|
877,952 | 877,952 | 877,952 | 877,952 | 877,952 | 877,952 | 877,952 | |||||||||||||||||||||
|
Fondo Mario
Negri(16)
|
168,619 | 168,619 | 168,619 | 168,619 | 168,619 | 168,619 | 168,619 | |||||||||||||||||||||
|
Termination
Indemnity(17)
|
| 280,925 | | | 842,774 | | 1,966,472 | |||||||||||||||||||||
|
Health and
Welfare(11)
|
98,845 | | | | | | | |||||||||||||||||||||
|
Outplacement(13)
|
25,000 | | | | | | | |||||||||||||||||||||
|
Non-Compete(18)
|
339,764 | 339,764 | 339,764 | | 339,764 | 339,764 | 339,764 | |||||||||||||||||||||
|
Jeffery A. McCaulley
|
||||||||||||||||||||||||||||
|
Severance
Salary(1)
|
1,027,600 | | | | | | | |||||||||||||||||||||
|
Severance EPIP
Award(2)
|
822,080 | | | | | | | |||||||||||||||||||||
|
2010 EPIP
Award(3)
|
411,040 | | | 415,890 | 415,890 | | | |||||||||||||||||||||
|
Stock
Options(4)
|
1,712,840 | 626,971 | 626,971 | 1,712,840 | 1,712,840 | 626,971 | 1,712,840 | |||||||||||||||||||||
|
Restricted
Stock(5)
|
927,054 | | | 927,054 | 927,054 | | 214,594 | |||||||||||||||||||||
|
RSUs(6)
|
1,732,683 | | | 674,811 | 674,811 | | 187,449 | |||||||||||||||||||||
|
Nonqual. Pension & Def. Comp.
|
||||||||||||||||||||||||||||
|
BEP/SIP(9)
|
1,286 | 1,286 | 1,286 | 1,286 | 1,286 | 1,286 | 1,286 | |||||||||||||||||||||
|
Health and
Welfare(11)
|
32,846 | | | | | | | |||||||||||||||||||||
|
Disability(12)
|
| | | | 3,125,608 | | | |||||||||||||||||||||
|
Outplacement(13)
|
25,000 | | | | | | | |||||||||||||||||||||
|
Gross-up(14)
|
1,186,759 | | | | | | | |||||||||||||||||||||
|
Jeffrey B. Paulsen
|
||||||||||||||||||||||||||||
|
Severance
Salary(1)
|
930,000 | | | | | | | |||||||||||||||||||||
|
Severance EPIP
Award(2)
|
651,000 | | | | | | | |||||||||||||||||||||
|
2010 EPIP
Award(3)
|
325,500 | | | 341,319 | 341,319 | | | |||||||||||||||||||||
|
RSUs(6)
|
1,289,072 | | | | | | | |||||||||||||||||||||
|
Health and
Welfare(11)
|
32,670 | | | | | | | |||||||||||||||||||||
|
Disability(12)
|
| | | | 2,300,128 | | | |||||||||||||||||||||
|
Outplacement(13)
|
25,000 | | | | | | | |||||||||||||||||||||
| (1) | Amount shown in Change in Control column represents two times the executives base salary in effect as of December 31, 2010. See the narrative that follows this table for a description of the change in control severance agreements we have with each of the executives. In the case of Messrs. Dvorak, Crines, McCaulley and Paulsen, the Company-Initiated (without Cause) column excludes severance payable under our severance plan for U.S. employees, which does not discriminate in favor of executive officers and is available generally to all salaried employees. In the case of Mr. Melzi, severance payable in the event of a company-initiated termination without cause is included in the termination indemnity described in footnote 17. | |
| (2) | Amount represents two times the executives target incentive award opportunity under the EPIP for 2010. | |
| (3) | Amount represents the actual amount payable to the executive under the EPIP for 2010 assuming the executive terminated employment effective December 31, 2010 as a result of the specified termination event. | |
| (4) | Amount represents the value of the executives in the money vested stock options (including otherwise unvested stock options, the vesting of which would accelerate as a result of the specified termination event). Value is calculated on the basis of the difference between the exercise price and $53.68, the closing price of our common stock on the New York Stock Exchange on December 31, 2010, multiplied by the number of shares of common stock underlying in-the-money options. |
| (5) | Amount represents the value of shares of restricted stock held by the executive that would be deemed fully vested as a result of the specified termination event. Value is calculated by multiplying the number of shares deemed fully vested by $53.68, the closing price of our common stock on the New York Stock Exchange on December 31, 2010. | |
| (6) | Amount represents the value of unvested RSUs held by the executive that would vest as a result of the specified termination event. Value is calculated by multiplying the number of unvested RSUs that will vest by $53.68, the closing price of our common stock on the New York Stock Exchange on December 31, 2010. | |
| (7) | Amount represents the present value of the executives accumulated benefit commencing at age 65 under the RIP assuming the executive terminated employment effective December 31, 2010 as a result of the specified termination event. The amount shown in the column captioned Death for each executive represents the benefit payable upon the death of the executive to his surviving spouse. The amount is equal to the retirement benefit payable at age 65, reduced to take into account the greater number of years during which the executive would have been expected to receive the retirement benefit had he retired on his date of death. The benefit is further reduced to an equivalent value form of annuity that pays a benefit to the executive for life and pays 50% of this amount upon his death to the surviving spouse for the surviving spouses life. The death benefit value is equal to the present value of 50% of this benefit amount payable to the executive over the life of the surviving spouse. | |
| (8) | Amount represents the present value of the executives accumulated benefit commencing at age 65 under the BEP/RIP assuming the executive terminated employment effective December 31, 2010 as a result of the specified termination event. See the narrative that follows this table for a description of the additional benefit amount included in the amounts shown in the column captioned Change in Control that would be payable in the event of a change in control. The amount shown in the column captioned Death for each executive represents the benefit payable upon the death of the executive to his surviving spouse. The amount is equal to the retirement benefit payable at age 65, reduced to take into account the greater number of years during which the executive would have been expected to receive the retirement benefit had he retired on his date of death. The benefit is further reduced to an equivalent value form of annuity that pays a benefit to the executive for life and pays 50% of this amount upon his death to the surviving spouse for the surviving spouses life. The death benefit value is equal to the present value of 50% of this benefit amount payable to the executive over the life of the surviving spouse. The amounts were determined using interest rates of 2.47% for the first 5 years, 5.07% for the next 15 years, and 6.10% for years above 20. The mortality table is the 2011 IRS mortality table. | |
| (9) | Amount represents the executives vested account balance in the BEP/SIP as of December 31, 2010. This amount will be paid in a lump sum unless an executive elects to receive payment of his account balance in annual installments. Only an executive who has attained age 55 and completed 10 years of service as of the date of termination may make this election. | |
| (10) | Amount represents the balance of the deferred compensation account under the EPIP as of December 31, 2010 for Mr. Dvorak. See Nonqualified Deferred Compensation in 2010 Executive Performance Incentive Plan on page 52 for more information about this plan, including available forms of payment and material conditions applicable to receipt of payments. | |
| (11) | Amount represents the cost of health and welfare benefits that the executive would be eligible to receive assuming the specified termination event occurred as of December 31, 2010. With respect to Mr. Melzi, the reported amount also includes the estimated cost of automobile-related expenses for a period of 24 months. | |
| (12) | Amount represents the present value of the executives benefit under our Long-Term Disability Income Plan for Highly Compensated Employees assuming the executive became disabled effective December 31, 2010. Under the plan as in effect as of that date, a participant would be entitled to a monthly benefit equal to 70% of his or her monthly base earnings (including salary, the average of the annual incentive earned for the year preceding the date of disability and the target annual bonus for the year in which the disability occurred, and sales commission, as applicable) reduced by the benefits payable under our base long-term disability insurance plan, supplemental insurance plan and certain other sources of income (including social security disability benefits). Benefits would be payable until the earliest of the following: (1) the date the participant ceases to be totally disabled; (2) the date the participant accepts or refuses a job we offer to him at a salary at least equal to that which he was earning immediately prior to becoming disabled; or (3) the participants 65th birthday (or a later date if benefits commenced under the plan after the participant reached age 631/2). The present value was determined by discounting the expected benefit payments using an interest rate of 5.82% and a mortality table for disabled employees. The present value excludes benefits payable under our base long-term disability insurance plan, which does not discriminate in favor of executive officers and is available generally to all salaried employees. The present value does include the benefit payable under the insured, supplemental insurance policy because that benefit is paid for by us, but is not available to all salaried employees. |
| (13) | Amount represents the estimated cost of outplacement services to be provided to the executive in the event of a change in control and termination of employment. | |
| (14) | See the narrative that follows this table for a description of gross-up payments to be made in the event of a change in control. | |
| (15) | Amount represents the present value of Mr. Melzis accumulated benefit under the Trattamento Fine Rapporto assuming he terminated employment effective December 31, 2010 as a result of the specified termination event. | |
| (16) | Amount represents Mr. Melzis account balance as of December 31, 2010 in the Fondo Mario Negri, a private fund to which we annually pay a percentage of Mr. Melzis salary in accordance with the Italian National Labour Collective Agreement for individuals graded as Dirigenti. | |
| (17) | Amount shown in the Company-Initiated (without Cause) column represents an estimate of a termination indemnity that would be due Mr. Melzi in the case his employment is involuntarily terminated as determined under Italian law. The termination indemnity consists of the following: a notice allowance (12 months of pay after 12 years of service) plus a supplementary allowance indemnity (a minimum of 12 months of pay and maximum of 18 months of pay) plus a seniority allowance (4 months of pay at age 62). For purposes of this table, we have assumed that the aggregate termination indemnity payment would be equal to 28 months of pay. Pay for this purpose includes salary, bonus and benefits. Amount shown in the Voluntary Resignation column represents compensation payable to Mr. Melzi if he were to voluntarily resign without just cause and without justified reason as determined under Italian law. This amount is equal to 4 months of pay. If Mr. Melzi were to voluntarily resign with justified reason as determined under Italian law, he would be entitled to 12 months of pay unless the justified reason was refusal to change his place of work, in which case he would be entitled to 16 months of pay. If Mr. Melzi were to voluntarily resign with just cause as determined under Italian law, he would be entitled to 16 months of pay. Amount shown in the Disability column represents compensation payable to Mr. Melzi if he were to resign following a continuous period of 12 months of sickness or injury. This amount is equal to 12 months of pay. | |
| (18) | Amount represents sixty percent (60%) of Mr. Melzis fixed base compensation during 2010 (the 365 days prior to Mr. Melzis assumed termination date). Pursuant to the non-competition agreement we have entered into with him, as is common under Italian law, Mr. Melzi would be entitled to receive such compensation, payable in three installments over the 18-month non-competition period, commencing upon termination of his employment for any reason other than death. |
| A | B | C | |||||||||||
|
Number of securities |
|||||||||||||
|
remaining available for |
|||||||||||||
|
Number of securities to be |
future issuance under |
||||||||||||
|
issued upon exercise of |
Weighted-average exercise |
equity compensation plans |
|||||||||||
|
outstanding options, |
price of outstanding options, |
(excluding securities reflected |
|||||||||||
|
Plan Category
|
warrants and rights (#) | warrants and rights ($) | in column (A)) (#) | ||||||||||
|
Equity compensation plans approved by security
holders(1)
|
18,557,973 | (2) | $66.76(3) | 14,290,551 | (4)(5)(6)(7) | ||||||||
|
Equity compensation plans not approved by security
holders(8)
|
259,688 | (9) | N/A(10) | 490,312 | |||||||||
|
Total
|
18,817,661 | $66.76 | 14,780,863 | ||||||||||
| (1) | Consists of the 2009 Stock Incentive Plan (2009 Plan), the 2006 Plan Stock Incentive Plan (2006 Plan), the 2001 Stock Incentive Plan (2001 Plan), the TeamShare Stock Option Plan (TeamShare Plan), the Stock Plan for Non-Employee Directors (Director Stock Plan), the Restated Deferred Compensation Plan for Non-Employee Directors (Director Deferred Compensation Plan) and the Employee Stock Purchase Plan. | |
| (2) | Includes shares which may be issued pursuant to the following outstanding awards: (a) 26,023 DSUs issued pursuant to the terms of the Director Deferred Compensation Plan, as described in footnote 6 below, and (b) 1,094,484 RSUs issued pursuant to the terms of the 2009 Plan, the 2006 Plan and the Director Stock Plan (assuming that outstanding performance-based RSUs are earned at the maximum award level). Also includes 103,664 options granted prior to our separation from our former parent with respect to common stock of the former parent which were replaced on August 7, 2001 with options to purchase our common stock. The replacement options were intended to preserve the economic value of the original options at the time of the separation. The number of shares of our common stock covered by replacement options was calculated by multiplying the number of shares of common stock of the former parent under the original options by a factor of 2.03614, and the exercise price of the options was decreased by dividing the original exercise price by the same factor. The weighted-average exercise price of the outstanding replacement options as of December 31, 2010 was $30.64. | |
| (3) | Represents the weighted average exercise price of outstanding options. Does not take into consideration outstanding DSUs or RSUs, which, once vested, may be converted into shares of our common stock on a one-for-one basis upon distribution at no additional cost. | |
| (4) | Assumes that outstanding performance-based RSUs are earned at the maximum award level. No shares remain available for future issuance under the 2001 Plan, the TeamShare Plan or the 2006 Plan. After stockholder approval of the 2009 Plan on May 4, 2009, an aggregate of 6,682,573 shares remaining available under the TeamShare Plan and the 2006 Plan were merged into the 2009 Plan, which provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, RSUs, performance units and performance shares. The maximum number of shares of our common stock that may be issued pursuant to awards under the 2009 Plan is equal to the sum of 11,682,573 shares, plus the aggregate number of shares underlying outstanding awards under the TeamShare Plan and the 2006 Plan as of May 4, 2009 that later terminate or expire or are cancelled or forfeited during the term of the 2009 Plan without having been exercised or fully vested; provided, however, that each |
| ZIMMER HOLDINGS, INC. 2011 PROXY STATEMENT |
| (5) | The Director Stock Plan provides for the grant of stock options, restricted stock and RSUs. A maximum of 2,000,000 shares of our common stock may be issued pursuant to awards under the plan. Of the 2,000,000 total shares that may be issued, not more than 500,000 shares may be issued pursuant to awards of restricted stock and RSUs. | |
| (6) | The Director Deferred Compensation Plan provides for the mandatory deferral of certain compensation payable to our non-employee directors in the form of DSUs. When amounts are deferred, a directors deferred compensation account is credited with that number of DSUs equal to the deferral amount divided by the fair market value of a share of our common stock. Such DSUs are payable in shares of our common stock after cessation of the individuals service as a director. A maximum of 200,000 shares of our common stock may be issued under the plan. | |
| (7) | Includes 2,274,134 shares available for purchase under the Employee Stock Purchase Plan. | |
| (8) | Consists of the Independent Sales Representatives Deferred Annual Final Compensation and Equity Incentive Plan, or the Sales Representative Plan, which is described below. | |
| (9) | This number is the sum of the actual deferred stock units awarded under the plan as of December 31, 2010 (249,983) and the number of deferred stock units that would have been awarded (9,705) if all outstanding stock option units as of December 31, 2010 (156,645) were converted into deferred stock units as of December 31, 2010. | |
| (10) | Deferred stock units are converted into shares of our common stock on a one-for-one basis upon distribution at no additional cost, but were acquired as described below. |

| M31328-P06563 | KEEP THIS PORTION FOR YOUR RECORDS | |||||
| DETACH AND RETURN THIS PORTION ONLY | ||||||
1. Election of Directors: |
||||||
Nominees: |
For | Against | Abstain | |||
1a. Betsy J. Bernard |
o | o | o | |||
1b. Marc N. Casper |
o | o | o | |||
1c. David C. Dvorak |
o | o | o | |||
1d. Larry C. Glasscock |
o | o | o | |||
1e. Robert A. Hagemann |
o | o | o | |||
1f. Arthur J. Higgins |
o | o | o | |||
1g. John L. McGoldrick |
o | o | o | |||
1h. Cecil B. Pickett, Ph.D. |
o | o | o | |||
| For address changes and/or comments, please check this box and write them on the back where indicated. | o | |||||
| THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSAL 2. | For | Against | Abstain | |||||
2. Non-binding advisory vote on executive compensation (say-on-pay) |
o | o | o | |||||
THE BOARD OF DIRECTORS RECOMMENDS A |
1 Year | 2 Years | 3 Years | Abstain | ||||
VOTE FOR 1 YEAR ON PROPOSAL 3. |
||||||||
3. Non-binding advisory vote on the frequency of say-on-pay votes |
o | o | o | o | ||||
| THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSAL 4. | For | Against | Abstain | |||||
4. Ratification of appointment of independent registered public accounting firm for 2011 |
o | o | o | |||||
| Address Changes/Comments: | |||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|